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INTRODUCTION 
 
 Siddha system is an ancient system of medicine and was found by siddhars 
who have attained siddhi [spiritual perfection]. Siddhars who really discovered the 
good of humanity are seers, thinkers and men of action. Siddha system plays a wide 
ranged role in the field of pediatrics. It ensures the health of the children with its 
astonishing herbal formulation. Children’s health reflects the nation’s health and 
wealth and they are most vulnerable group in the society. They become ill easier since 
they aren’t built with a good immune system and they are exposed to several 
pathogens from the surrounding environment.   
  
 Siddha system of medicine is based upon the 96 Thaththuvangal. Among that, 
pancha boothas [five elements are earth, water, space, fire, air] and the three Uyir 
Thathukkal [Three humours- Vadha, Pitha, and Kapham] got prime importance. The 
disturbance in the equilibrium of the three humors cause the disease. It’s explained by 
thiruvalluvar in his kural,    
 
  “                            
                   ”. 
 
 It serving the mankind to all of its physical and mental, social and spiritual 
components of human beings. The advantage and unique feature is the removal of 
root cause of the disease and perfect for body and mind. 
 
 Skin is the largest organ in human body.Skin and its derivatives and 
appendages form the integumentary system. Skin derivatives includes nails, hair and 
several types of sweat and sebaceous glands. The skin forms protective covering of 
the body skin develops in the third week of the fetal life. The skin at birth is covered 
by vernix caseosa. The whitish greasy coats have bactericidal properties.  
There are so many skin diseases like vitiligo, Lichen planus, Psoriasis, 
Scabies, Pityriasis alba affecting the children. Most common childhood skin disease is 
eczema.  
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 In our classical siddha literature there are 18 types of Eczema (karappan) have 
been described, Signs and symptoms of eczema is nearly co releated to “BALA 
KARAPPAN” mentioned in siddha system of medicine (Balavagadam). According to 
the siddha text it is characterized by skin rashes, papules, vesicles, pustules, fissures, 
oozing, ulceration, swelling, itching, hyperpigmentation lesion. The trial drug 
“SAARANAI ENNAI” (internal and external medicine) indicated for Bala 
Karappan is comparatively safer than synthetic drugs, this poly herbal preparation 
may be effective to manage Bala Karappan.  
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AIM AND OBJECTIVES 
 
AIM:  
To evaluate the efficacy and safety of the siddha medicine “Saaranai ennai” in 
the treatment of “Bala Karappan” (Atopic Dermatitis) in children. 
OBJECTIVES: 
Primary objective: 
 To study the efficacy of Saaranai ennai in the treatment of  Bala Karappan 
(Atopic Dermatitis) 
 To study the safety of the trial medicine Saaranai ennai. 
Secondary objective: 
 To have a detailed analysis of the safety of the drug through 
 Toxicity studies 
 Pharmacological studies 
 Physico chemical analysis. 
 Phyto chemical analysis 
 To collect and review the ideas of Bala Karappan mentioned in various siddha 
literature in the aspects of Definition, aetiology and Clinical features. 
 To make a correlative study of the Siddha aspect and Modern aspect of my 
study Bala Karappan. 
 To record the incidence of the disease with regard to age, sex, socio-economic 
status, history of food habits and drug ingestion. 
 To have an extensive study that how the disease alters the normal conditions 
which are dealt under Mukkutra Verupadugal, Envagaithaervu, 
Udalthaathukkal, Paruvakaalangal, Neerkuri, Neikuri. 
 To determine the effect of trial drug by AEC & ESR 
 To determine the clinical symptoms reduction in EASI (Eczema Area Severity 
Index) Score. 
 To use the possible modern parameters in the investigation of the disease, that 
enhances to observe the progress of the patient. 
 To have a clinical trial, to find out  the efficacy of the trial medicine “Saaranai 
ennai” (Internal & External medicine) in the treatment of Bala Karappan 
(Atopic Dermatitis) in children. 
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REVIEW OF LITERATURES 
SIDDHA ASPECTS 
 
Bala Karappan is one of the eighteen types of Karappan which affects the 
children. This skin disease was described by various Siddhars in detail about the 
general etiology signs and symptoms and prognosis. 
 
fug;ghd; 
,ay; (Definition) 
clypy; jpkpu;> jpdT> nrhwp> Gz;> jbg;G> ntbg;G> ePu; frpjy; Mfpa Fwp 
Fzq;fs; cz;lhf;fp clk;gpd; ,aw;if epwj;ij NtWgLj;Jk; Neha; fug;ghd; 
vdg;gLk;. 
Neha; tUk; gUtk; 
jhy gUtk; Kjy; tUif gUtk; tiuAs;s ehd;F gUtq;fspYk; 
fug;ghd; Neha; Foe;ijfSf;F cz;lhff;$Lk;. 
Neha; tUk; top (Etiology) 
In Text book Balavagadam, it desccibed the etiology of Karappan as, 
“ngUFQ; Nrhs kpWFk; ngUq;fk;G 
tuF fhUld; thioapd; fhnahL 
ciunfhs; ghfw; nfspw;W kPd; cz;bby; 
tpuptjha;f; fug;ghD kpFe;jNj”. 
In take of Fish, Mutton, rhizomes, Tubers of some plants and grains like, 
Kambu (Pennisetum typhoideum), Solam (Sorghum vulgarel, Varagu (Paspalum 
Scrobicculatum), Karrasi (Oryza Sativa), Vazhaikkai (Muza Paradisiac), Paakal 
(Momordica Charantica), Kelirrumean (Osteogeniosus militaris) taken by the mother 
(By breast feed) or child produces Karappan. 
According to siddha literature yugi vaidhya chinthamani: 
According to Siddha text book Yugi Vaidhya Chinthamani etiology of 
Karappan described by eating meat, various types of millet and tubers can cause 
Karappan. 
“Vohd fug;ghdpd; cw;gj;jpf; Nfsha; 
Vw;wkha; khkprq;fs; Grpf;ifahYk; 
$ohd fk;G jpid tuF rhikf; 
nfhbjhd fpoq;F tifaUe;j yhYk”.; 
- A+fp itj;jpa rpe;jhkzp              
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According to siddha literature Pararasa Segaram: 
        According to the Siddha literature Pararasa Segaram etiology of Karappan 
described as Air born infection, Excessive intake of Jaggery, Plantain, Brinjal, 
poisonous bites may cause the disease. 
“Ntff; fhw;wjpdu; gid nty;yj;jhy; 
ghfkpf;fyhd Nkjpg; ghntapyhy;  
jhfkhdp tUf;f jprhu;jyhy; 
Nkhf thio tOjiy Ks;spf;fha; 
fhAk; gy;tplj; jhw;Ruj; jhw;fspy; 
vAk; tz;nlyp ahy; tUNk Jntsp 
Fb ey;ywpthd vUtpdhu; 
ahdkhd fug;gd; tiffNs”. 
- guuhr Nrfuk;. 
 
Classification of karappan: 
           As per the Siddha literature Bala vagadam, Karappan is classified into eighteen 
types as follows, 
“Kj;Njhl kupA+J #iy 
Kd;Dntb kz;il nghuprl;il 
rw;NwL fUiknahL nrk;ik. 
jdpf;nfhs;sp NjhlnkhL thiy 
Kw;Nwhy;t ul;rpnahL tPq;fy; 
%uptUk; gjpndl;L tifahk; 
nfhj;jhd fug;ghd;f nsd;W 
$wpdhu; gz;ilNah uhkhy;” 
 
“nrq;fug;ghd; mdy;fug;gd; jhDk; kz;ilr;        
rpuq;fpggz;Zk; mupfug;ghd; nghupf ug;ghd; 
mq;fkjp nyOfug;gd; jhD kpf;f 
msuhk; cjp uf;fug;gd; fl;b NahL 
nghq;fkha; tPq;fp fug;ghd De;jhd; 
Gfyupa rl;iljb ntbf ug;ghd; 
rpq;fKf vhpfug;gd; thj gpj;jr; 
Nrj;Jkj;Njh Nlfug;gd; gjpndl; lnk 
vz;tiff; fug;gd; ,ire;jplf; NfS”. 
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Classification of karappan as per the text book of bala vagadam 
1. Vatha Karappan (thj fug;ghd;) 
2. Pitha Karappan (gpj;j fug;ghd;) 
3. Sethuma Karappan (Nrj;Jk fug;ghd;) 
4. Ari Karappan  (mup fug;ghd;) 
5. Oothu Karappan (CJ fug;ghd;) 
6. Soolai Karappan (#iy fug;ghd;) 
7. Vedi Karappan (ntb fug;ghd;) 
8. Mandai Karappan (kz;il fug;ghd;) 
9. Pori Karappan  (nghup fug;ghd;) 
10. Sattai Karappan (rl;il fug;ghd;) 
11. Oodu Karappan (XL fug;ghd;) 
12. Karung Karappan (fuq;fug;ghd;) 
13. Seng Karappan (nrq;fug;ghd;) 
14. Kolli Karappan (nfhs;sp fug;ghd;) 
15. Thoda Karappan (Njhl fug;ghd;) 
16. Vaalai Karappan (ghy fug;ghd;) 
17. Varal Karappan (tus; fug;ghd;) 
18. Veengu Karappan (tPq;F fug;ghd;) 
  
1. thj fug;ghd;: 
“njwpf;Fk; tPq;FKl nyq;F Nkjpkpu;f Lg;g jfpaOe; NjfNkw; 
nghwpg; gwe;jnjd NtGz; zhfpa jp Nyntbj; jjpf nghq;fkha; 
KWf;fp NaRuk jhfp ehtJ twz;L NehaJ Kjpu;e;jpby;  
ntwpf; fUq;Foyp khJ thjfug; ghnddg; Gfy;tu; NktpNl”. 
- (ghy thflk; 4k; gjpg;G gf;f vz; 385) 
 Skin rashes or bumpy rashes 
 Papules/ Vesicles/Pustules
 Oozing fromlesion
 Lymphadenopathy
 Itching
 Fever

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2. mow;fug;ghd;: 
“nfhLikahd rpuNehapNdhL nrhwp $W Kl;bdKk; the;jpAk; 
fLikahd Runka;rp te;jpLjy; fz;guj; Jnjhdp Ke;jpNa 
jilfshfky ge;jkhfptpby; rhu;e;j gpj;jfug; ghndd;Nw 
tplK NeuKj KQ;rkhdtpop ntz;z ifj;jpU kUe;jpNl”. 
 Headache 
 Itching 
 Vomiting 
 Fever 
 Reddishness in affected skin 
 Constipation 
 
3. Iaf;fug;ghd;: 
“,irA neQ;Rf silj;J Nstpuz khfpNajit typj;jpLk; 
mirAk; thajdpy; nte;JNk jpul;rpafp NafL fLj;jpby; 
tpirAQ; Nrj;Jk fug;ghndd rpfpr;irNkT nrt;tup gue;J epd; 
tir nghUe;Jk; tpop fiyjpuz;lKf tdpijNa Tljq;fNs”. 
 Ulcers in the mouth and trunk 
 It changes to vesicles 
 Chest pain 
 Headache 

4. mupfug;ghd;: 
“,ilrp Wj;Jtd fdpG iuj;j nkhop apdpajhdtj uj;jpdha; 
Jilap ilf;Fs;kpF tpuz khfpajpw; #or yq;ffSkp Fe;JNeha; 
GilA ePs;jir fiue;J el;gltp Ue;J G+jTly; thbdhy; 
milt Nrhup fug;g dhkpija wpe;J ed;kUe; jhw;wpNl”. 
 Ulcers in the genital organs and both groins
 Itching and oozing in the inner aspect of the thigh 
 Emaciation 
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5. CJ fug;ghd;: 
“Nfsha; Fspu;fha;r;ry; Nflhq; fUq;foiy 
%shtp jhd; Nghy; Kad;Wepw;Fk; - ehs;NjhWk; 
G+jk;Nghy; tPq;Ftpf;Fk; Gz;zhfp %f;fupf;Fk; 
CJfug; ghe;Njhlk; cw;W”. 
 Fever with rigor 
 Tumours in the body 
 Generalised oedema and Itching 
 
6. #iyf; fug;ghd;: 
“gps;is Kfk;thbg; Ngjntb Nkdpnay;yhk; 
rs;is nghUe;jpj; jtpf;FNk – nks;sf;Nfs; 
ts;sy; Koq; fhy;if kUtpAz;zf; $lhJ 
js;Snkd;Nw #iyaJ jhd;.” 
 Ulcers and pain in the body and general debility 
 Difficulty in moving both knees and elbow joints 
 
7. ntb fug;ghd; 
“mupit NaAlyfnsq;Fk; tpq;FkirfPypy; tPq;Fkjpy; Jz;lkha; 
tpupa tPq;fpajp nyntbj;jpL kpFe;j ntg;gJT khfNt 
jpupfp Najiy typj;J NkYk;ntF jpdT khfpaJ Nthbdhy; 
cupa jhFk;ntb fug;g dhnkd Tfe;J gz;bj Kzu;j;jpNl”. 
 Swelling in the body 
 Pain and swelling all over the joints
 Itching, headache, and fever
 
8. kz;ilf; fug;ghd;: 
“Xb kz;iljdp NyGz; zhfpAau; fhjpw; rPtope;jwpNa  
ehb Najiyt ypj;J %f;fpdpy; eae;J epuJ g;upe;jpLk; 
thb nka;aJk; ntg;gnkhL Fuy; tisap dpdwpdTkhfNt 
$by; kz;ilf; fug;ghnd dg;gup fhu Nkypdpf; $Wthk;”. 
 Itching in the scalp
 Ear discharge, headache, and fever 
 Loss of weight and pain in the throat 
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9. nghupfug;ghd;: 
“khW khnwd tbjj tnad Tlw;FNs jbg;ghfpNa 
VW Nkrpte; NjhL Nafdj; njq;F Nky;ntbj; Js;SNk 
ePW Nghydy; Fspu;r;rp ahfpAo dhT yu;e;Jnewp jho;j;jpby; 
Mwp lhg;nghwp fug;g dhnkd twpe;J gz;bje; njhFj;jpNl”. 
 Papules in the body and altered sensorium
 Dryness of mouth 
10. rl;ilf; fug;ghd;: 
“kq;if fPypy;typ fs;spg; G+ntdk yu;e;J thupapL nka;apdpw; 
Nghq;F ePu;g; gdpfs; Nghy;tp Ke;Jlyk; ntg;g khfpkyQ; rpf;fpNa 
Jq;f khdrpu NehT khfptsu; J}atd;dkJ JNtlkhk; 
jq;F rl;il fug; ghNd zr;rpfpr;ir jhNd jw;Ftpupj; NjhJtha;”. 
 Pain in all the joints associated with fever 
 Yellow colouration of the skin 
 Itching and oozing in the lesion 
 Loss of appetite 
11. XL fug;ghd;: 
“vz;Z fpd;wnjhU fPyp Nytypf Nsf khfpaJ fl;bNa 
tz;z nka;euk; ngq;F NkaprpT Fj;j yhfpky ge;jkha; 
ez;zp NajpdT kha;j;jbj; Jlyp db tPf;fK kpFe;jpbw; 
fz;zp xLfug; ghd;, njd;wKiw fz;L nfhs;sb fUj;jpNy”. 
 Pain and swelling in all the joints
 Difficult to flexion and extension of joints 
 Allergic papules 
 Itching
 Constipation 
12. fUq;fug;ghd;: 
“mw;a Nfsa; fuq;fug;gd; monk Fotp cly;ntJk;Gk; 
nrwpa KiyAk; cz;zhJ Njfepw;Fk; ntt;Ntwha;f; 
fupa Nkdp gReuk;G fjpj;Nj fhl;Lk; guguj;J 
KWf;fp kpfTe; Js;sp tpOk; KfKk; gjq;fs; CjpLNk”. 
 Fever 
 Discolouration of the skin 
 Oedema in the face and lower limbs 
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13. nrq;fug;ghd;: 
“fha;r;r NyhLfLg; gfp A+jply; fd;wp nkj;jT kod;WNgha; 
Nka;r;r yhdjpd thfpnaq;fZ tpau;f;FUTfs; kpFe;Jjhd; 
gha;r;r yhdKf Kq;fWj;Jly; gupe;J jhdJ rpte;jpby; 
#l;r khfptsu; nrq;f ug;gnddj; Njhw;wp NaaT ljQ;nrNa”. 
 Low grade Fever
 Macules and papules are present 
 Blackish discolouration in the face 
 Erythematous lesion present in all over the body 
14. nfhs;spf; fug;ghd;: 
“nfhj;Jf; nfhs;sp apd;fug;ghd; Fzj;ijf; Nfsha; NfhfpyNk 
kw;Wk; tapW jhd;tPq;fp kyK kilf;Fk; ,isg;Gz;lhk; 
fj;Jq; FuYk; miuAz;lhq; fdj;j tpf;fy; cz;lhdhy; 
gj;Jk; gjpAk; xJtNjd; ghyd; gpiog;g jupjhNk”. 
 Abdomen swelling
 Constipation
 Emaciation
 Hiccough
 Dyspnoea
15. Njhlf; fug;ghd;: 
“cs;S NkYespu; fha;r;r yhfpAlk; ngq;Fk; Gz;nzd tod;Wtha; 
fs;S ehwpAly; jd;dp Nyfoiy fz;L G+jnkd tPq;fpNa 
vs;spd; khkyiu nahf;F %f;fpd; epd;wOJ Nkq;fpdhy; 
js;S khd;fspd; rha yha; nfhbaNjh lkhdfug; ghdpNj”. 
 Fever with rigor
 Papules and pustules in the body
 Foul smell in mouth  
 Lymphnode enlargement
 Itching innose 
16. thiy(ghy) fug;ghd;: 
“fhyJ fLf;FQ; re;J fz;lKk; ntbj;Jg; Gz;zha; 
VyNt fbtp lk;Nghy; ,Uj;Jgd; dPu;Ngy; gha;e;J 
Nfhykha; tw;wp ehWk; FotpA nkhLq;F khfpy; 
khyUq; Foyha; thy fug;ghd; nra; thW jhNd”. 
 Pain in the lower extremities
 Appearance of vesicles, oozing, bullae, papules
 Foul smelling discharge in the ulcers 
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17. tus; fug;ghd;: 
“cr;rpKj Ys;sq;fh Yw;wstp nyt;tplKk; 
er;Rr; rpWrpuq;F ez;zpNa-epr;ry; 
ntbj;J ePu; nkT eik nkth Jwf;fk; 
fbe;jtul; rpf;fug;ghd; fhz”. 
 Itching, Oozing, papules in the body
 Bullae present in the whole body
 Insomnia
 tPq;F fug;ghd;:
“Kd;dNu aq;fq;F %upf; fdKz;lha;g; 
gpd;duit Gz;zha;g; ngU/jPaha;g-kd;dpnaupe; 
jg;ghd Kj;jzpe;jtw;wp dPu; nrhupjy; 
jg;ghtpq; Fq;fug;ghd; jhd;”. 
 Swelling in various parts of the body 
 Burning sensation in the site of the lesion 
 Oozing 
Other Siddha Literatures describing the classification of Karappan 
As per the another siddha text book “Aathma rakshamirtham yennum vaithiya 
saarasankiram” describes the classification of Karappan in eighteen types as follows, 
a) Mj;kh uj;rhkpu;j;nkd;Dk; itj;jpa rhurq;fpuk; 
1. thjf; fug;ghd; 
2. gpj;j fug;ghd; 
3. rpNyj;Jk fug;ghd; 
4. nrq;fug;ghd; 
5. fUq;fug;ghd; 
6. kz;il fug;ghd; 
7. mup fug;ghd; 
8. nghup fug;ghd; 
9. fpue;jpf; fug;ghd; 
10. #iyf; fug;ghd; 
11. thiyf; fug;ghd; 
12. CJ fug;ghd; 
13. nrt;thg;G fug;ghd; 
14. nfhs;sp fug;ghd; 
15. fl;bnahLtpq;F fug;ghd; 
16. cjpuf; fug;ghd; 
17. rl;iljbntb fug;ghd; 
18. rpq;fKf vhp fug;ghd 
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b) A+fp itj;jpa fhtpak; 
          As per the siddha literature Yugi vaithiya kaaviyam karappan is classified into 9 
types as follows, 
1. thjf;fug;ghd; 
2. fz;lf;fug;ghd; 
3. twl;rpfug;ghd; 
4. gpj;jfug;ghd; 
5. gpj;jtwl;rpf;fug;ghd; 
6. fghy fug;ghd; 
7. thjtwl;rpf;fug;ghd; 
8. jpkpu;thjf;fug;ghd; 
9. nrq;fug;ghd; 
c) rpfpr;rhuj;d jPg itj;jpa rpe;jhkzp 
               As per the siddha literature Sigicha rathna theepam, karappan is classified 
into 7 types as follows, 
1. thjf; fug;ghd; 
2. jpkpu; fug;ghd; 
3. fghy fug;ghd; 
4. fz;lf; fug;ghd; 
5. gpj;j fug;ghd; 
6. twl;rp fug;ghd; 
7. rpNyj;Jk; fug;ghd; 
d) FUehb rh];jpuk; 
            Other Siddha Literature Guru naadi saasthiram, Karappan is classified into 
eighty five as follows, 
“gLtd; Kg;gj;jpuz;L gUntU ehw;gj;njhd;W 
KUfpLk; tp\gkhW Kw;Wnkh\rp %d;Wu; 
jpUfpLk; gPyp %d;W rpurpdpw; rpye;jp nrhy;ypy; 
fLfpL iklk; gj;jhW fug;ghD nkd;gj;ije;J”. 
- (FUehb rh];jpuk;) 
e) mfj;jpau; 2000 
          In Agathiyar 2000 classification of Karappan is sixty six in numbers 
“tpsk;gpL thjnehT vz;gj;J ehYkpf;f 
cs;sq;fs; rd;dp Kg;gNjhq;Fly; thAnkl;L 
foq;fK Kg;gj;njO fug;ghD kWg;gj;jhW 
jdq;nfhs;spg; GUjp ehY rhw;Wis Fwit nal;Nl”. 
- (mfj;jpah; 2000) 
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f) mfj;jpau; ,uz E}y ; 
In agathiyar irana nool classification of Karappan is sixty six in numbers 
“vz;gJ fug;ghd; jd;ik apak;gpLkhW NfsPu; 
ed;apLk; thjk; gpj;jk; eyq;nfl;Lj; jhsk;tpq;Fk; 
Gz;gLq; fuq;fs; re;J Giye;jply; fUj;J NehFk; 
td;ikAld; ntbj;Jr; #iy tUtJuig njd;nt”. 
- (mfj;jpau; ,uz E}y;) 
g) A+fp itj;jpa rpe;jhkzp 
         As per the Siddha literature Yogi Vaithiya Chinthamani Karappan is classified 
into seven types 
“Mnkd;w fug;ghd; jhd; VOtpj khFk; 
mlq;fhj thjj;jpd; fug;ghNdhL 
fhnkd;w fz;lkhq; fug;ghdhFk; 
fUjpa Njhu; twl;rpahq; fug;ghNdhL 
Njnkd;w jpkpu;thjf; fug;ghd; whDk; 
RpurpdpNy ngUf ghyf; fug;ghd; 
Nghnkd;w gpj;jkhq; fug;ghNdhL 
ngupa Nrl;Lkf; fug;ghd; ngau;jhNdNo”. 
- (A+fp itj;jpa rpe;jhkzp) 
 
1. Vadha Karappan              (thj fug;ghd;) 
2. Pitha Karappan                (gpj;j fug;ghd;) 
3. Kabha Karappan              (fg fug;ghd;) 
4. Kanda Karappan              (fz;l fug;ghd;) 
5. Varatchi Karappan           (twl;rp fug;ghd;) 
6. Kabala Karappan             (fghy fug;ghd;) 
7. Thimir Vatha Karappan   (jpkpu;thj fug;ghd;) 
 
Curable and incurable types of karappn as per siddha text book baavagadam 
1. nfhs;sp fug;ghd; - mrhj;jpak; (Incurable) 
2. kw;w 17 tiffs; - rhj;jpak;(Curable) 
 
Kf;Fw;w NtWghLfs; (Pathogenesis) 
     rpj;j kUj;Jtj;jpy; Kf;Fw;wq;fspd; mbg;gilapy; Neha;fs; 
tifg;gLj;jg;gl;Ls;sd. Kf;Fw;wwq;fshtJ thj> gpj;j> fgk; vd;W 
$wg;gl;Ls;sJ mit KiwNa 
       thjk; -10 
       gpj;jk; -5 
       fgk;  -5 
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thjk; / tsp (Vatham) 
tbtj;jd;ik 
 Ez;ik (mZj;Jtk;) 
 neha;ik (fbdkpd;ik) 
 jd;ik (Fspu;r;rp) 
 ntk;ik (cl;bzk;) 
jd;ik> ntk;ik Mfpa ,t;tpuz;lhy; tUk; xg;Gutpd;ik (rUr;riu) 
vd;gdthk;. 
 
tsp thOkplk; (Location of Vatham in the body) 
     mghdk;> kyk;> ,lfiy> ce;jpapd; fPo; %yk;> fhkf;nfhb> ,Lg;G 
vYk;G> 
Njhy;> euk;Gf;$l;lk;> fPy;fy;> kapu;f;fhy;fs;> Cd; Mfpa ,lq;fspy; 
tho;tjhFk;. 
 
tiffs; gzpfs; 
1. gpuhzd; 
%r;R thq;fy;> tpLjy; nra;Ak;. 
Grpf;Fk; czTfisr; nrupf;fg; gz;Zk; 
2. mghdd; 
(fPo;Nehf;Ffhy;) 
kyrj;ijj; js;Sk; 
Mrdthiar; RUf;Fk; 
md;drhuj;ijr; Nru Ntz;ba ,lq;fspy; 
Nru;g;gpf;Fk 
3. tpahdd; 
cWg;Gfis ePl;l klf;fr; nra;jy; 
guprq;fisawpjy; 
cz;Zk; cztpd; rhuj;ij mt;tt;tplq;fspy; 
epug;gpj;J cliyf; fhf;Fk 
4. cjhdd; (Nky; 
Nehf;Ff;fhy;) 
cztpd; rhuj;ij mq;fq;Nf epWj;Jk;. 
ntspg;gLj;jpAk;/ fyf;fpAk; tUjy; nra;Ak; 
5. rkhdd; (eLf;fhy;) 
thAf;fis kpQ;rnthl;lhky; klf;fpr; rupgLj;jp 
Nrugz;Zk;. 
jz;zPu;> md;dk; Mfpatw;iw rkg;gLj;jp 
clypnyy;yhk; NrUk;gb nra;Ak; 
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6. ehfd; 
mwpit vOg;gy;. ey;y gz;fisg; ghLtpf;Fk;. 
fz;fis jpwf;f ,ikf;fr; nra;Ak; 
kapu;fis rpypu;f;fg; gz;Zk 
 
7. $u;kd; 
,iria nfhl;Ltpj;jy; 
nfhl;lhtp tplg;gz;zy; gyk; cz;L gz;zy; 
fz;fis jpw;f;f/%l gz;zy;. 
cyfg; nghUl;fs; ahtw;iwAk; fz;fSf;F 
fhz;gpf;Fk;. 
fz;fspdpd;W ePiu tpog; gz;Zk 
8. fpUfud; 
ehtpw;frpT> ehrpapw; frpitAk; cz;lhf;fy;. 
grpia cz;L gz;zy; 
xd;iw epidj;jpUf;fr; nra;jy; 
Nghjw; njhopiyr; nra;Ak; 
Jk;kayak;> ,UkiyAk; cz;lhf;fy; 
9. Njtjj;jd 
rz;ilnfhs;sy; 
ju;f;fk;Ngry;> kpf;f Nfhgk;. 
10. jdQ;nrad; 
%f;fpypUe;j jbjJ clk;G KOikAk; tPq;fg; 
gz;Zk;. 
fhjpy; fly; NghypiuAk;. 
fhw;nwy;yhk; ntspg;gl;l gpd;du; 3tJ ehspy; 
jiy 
ntbj;j gpd; jhd; NghFk; 
 
ghyf; fug;ghdpy; mghdd;> cjhdd;> rkhdd;> fpUfud;> Njtjj;jd; 
,itfs; nghJthf ghjpg;G milAk;. 
 
gpj;jk;/moy; (Pitham) 
tbtj;jd;ik 
 ntg;gk; 
 nea;g;G 
 $u;ik 
 nefpo;r;rp 
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gpj;jj;jpd; ,Ug;gpld;: 
gpq;fiy> gpuhzthA> ePu;g;ig> %yhf;fpd;> ,Ujak;> jiy Mfpa 
,lq;fspy; tho;tjhFk;. 
 
tiffs; gzpfs; 
1. mdu;gpj;jk; cz;l czit nrupf;Fk;gb nra;Ak; 
 
2. ,uQ;rfk; 
nre;ePiu kpFjpgLj;Jk;. 
cztpd; rhw;Wf;F nre;epwj;ijf; nfhLf;Fk; 
3. rhjfg;gpj;jk; 
epiwNtw;Wk; gz;GilaJ 
kdk;> Gj;jp> gw;W ,tw;iwf; nfhz;L      
   tpUg;gkhd njhopiyr; nra;J Kbf;Fk 
4. MNyhrfg;gpj;jk; 
fz;fSf;F nghUl;fisj; njuptpf;Fk; 
   gz;GilaJ. 
5. gpuhrf gpj;jk; 
NjhYf;F Xspiaf; nfhLj;J xspur;     
   nra;Ak; 
 
ghyf; fug;gdpy; ,uQ;rfk;> gpuhrfk; ,itfs; nghJthf ghjpg;G milAk;. 
Iak;/fgk; (Kabham) 
tbtj;jd;ik 
jd;ik 
ke;jk; 
nea;g;G 
jpz;ik 
tOtOg;G 
nkd;ik 
 
Iak; thOkplk; 
 rkhdthA> RopKid> ntz;zPu (tpe;J)> jiy> ehf;F> cz;zhf;F> 
nfhOg;G> kr;ir> FUjp> %f;F> khu;G> euk;G> vYk;G> ngUq;Fly;> fz;> fPy;fs; 
Mfpa ,lq;fspy; tho;tjhFk;. 
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tiffs; gzpfs; 
1. mtyk;gfk; kw;w ehd;F Iaq;fl;F gw;Wf; NfhlhapUj;jpy; 
2. fpNyjk; 
czTg; nghUs;> ePu; ,itfis 
 <ug;gLj;jp nkj;njdr; nra;Ak; njhopiyg;     
 GupAk;. 
3. Nghjfk; 
ehtpdpd;W cz;Zfpw Ritfis mwptpf;Fk; 
 njhopiyg; GupAk 
4. jw;gfk; jiyapdpd;W fz;fSf;F Fspu;r;rpiaj; jUk;. 
5. re;jpfk; 
G+l;Lfspy; epd;W ,aw;ifaha; vy;yh    
 fPy;fisAk; xd;nwhnlhd;W nghUj;jp jsur;   
 nra;J nfhz;bUf;Fk;. 
 
ghyf; fug;ghdpy; Iak; nghJthf ghjpg;G milahJ. 
 
Diagnostic Methods (Piniyarimuraimai) 
Piniyari Muraimai is the methods of determination of a disease. It is bassed on 
the following principles. 
        1. Poriyalarithal (Inspection) 
        2. Pulanal arithal (Palpation) 
        3. Vinaathal (Interrogation) 
Poriyalarithal and pulanal arithal goes hand with the concept of Examining the 
patient’s pori and pulan with that of physician’s pori and pulan. 
Vinaathal is a method of interrogation about the details of that patients 
problem from his own words (or) from his parents or neighbours who are taking care 
of the patients, when the patient is not able to speak (or) patient may be child. 
 
rpj;j kUj;Jtj;jpd; Neha;fzpg;gpy; gpd;tUk; fhuzpfs; Kf;fpa gq;F 
tfpf;fpd;wd. 
Nehahspiar; rhh;e;jJ: 
 
1. caph; jhJf;fs; (Kf;Fw;wk;) 
2. cly; jhJf;fs; (VO clw;fl;Lfs;) 
3. vz;tifj; Njh;T 
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4. nghOJ 
1. rpWnghOJ  - itfiw> tpbay;> vw;ghL> ez;gfy;> khiy> 
ahkk; 
2. ngUk;nghOJ- fhh;> $jph;> Kd;gdp> gpd;gdp> ,sNtdpy;> 
KJNtdpy 
5. Itif epyq;fs;   - FwpQ;rp> Ky;iy> kUjk;> nea;jy;> ghiy. 
Nkw;$wpa fhuzpfspd; khWghLfis xd;Wld; xd;W xg;gpl;L Neha; 
fzpf;fg;gLfpwJ. 
 
Ennvagai thervugal (eight fold examination) 
 
            Envagai thervugal is a tool and it is described by Siddhar theraiyar as follows 
“ehbg; ghprk; eh epwk; nkhoptpop 
kyk; %j;jpu kpitkUj;Jt uhAjk;”. 
- Njud; 
 
The above concept also supported by another great Siddhar Agasthiyar in 
Vaidhya Chinthamani Venba – 4000 as follows, 
“nka;Fwp epwk; njhdp tpop eh ,Ukyk; iff;Fwp” 
 
Another Siddha book describe Envagal thervugal as follows, 
“Njba tpahjpf; nfy;yk; Njfj;jpy; ghpl;irAz;L 
$bNa epw;Fnkl;L ghpl;irahq; $wf;NfsPh; 
ehbNa njhl;lhw; Njfk; %j;jpuk; thh;j;ij fz;fs; ehf;F 
ghbNa kyryq;fs; gy tz;zk; ghh;j;Jf; nfhs;Ns”   
- rpj;j kUj;Jtkzpfs; 
Nkw;$wpa ghlypd; %yk; ehb> ];ghprk;> eh> epwk;> nkhop>tpop> kyk;> 
%j;jpuk; Mfpad kUj;Jthpd; MAjk; Nghd;wit vd mwpayhk;. 
 
Hence the diagnosis is made by using the following tools are important in Siddha 
system of Medicine: 
1. Naadi (Pulse reading) 
2. Sparisam (Tacfile sensation) 
3. Naa (Tongue) 
4. Niram (Colour) 
5. Mozhi (Speech (or) Voice) 
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6. Vizhi (Eye) 
7. Malam (Stools) 
8. Moothiram (Urine) 
1. Naadi 
             “clypy; caph; jhpj;jpUg;gjw;F fhuzkhd rf;jp vJNth mJNt ehb” 
Naadi is the vitiating elements of the body such as Vatham, Pitham, Kabam. 
Naadi is otherwise called a Uyir thathukkal. 
Naadi can be felt by a Physician viz Vatham, Pitham and Kabam with the tips 
of Index, Middle and Ring fingers respectively at the anterior part of lower end of the 
radius bone of the patients. It informs the physiological and pathological condition of 
the body. 
The three Uyirthathukkal are formed by the combination of 
Edakalai + Abanam  = Vatham 
Pinkalai + Piranan  = Pitham 
Suzhumunai + Samanan = Kabam 
The ratio between Vatham, Pitham and Kabam is 1:1/2:1/4 respectively. 
In Bala Karappan, Vatha naadi generally affected and then other naadi’s are 
also deranged. 
 
2. Sparisam 
The following points are elicited through sparisam. Temparature of the skin, 
Hypersensitiveness and thickness of the skin, swelling and dryness of the skin, ulcers, 
oedema, obesity, liver and spleen enlargement. 
In Bala Karappan, the skin becomes well defined borders, with clear central 
hyperpigmentation 
 
3. Naa 
This is the method of inspection of the tongue, gums, teeth, lips, palate etc., 
 
4. Niram 
Changes in the colour of the skin, teeth, eyes, nail and lips due to Mukkutra 
derangement are to be noticed Hypo (or) hyperpigmentation is also be noted.  
In Bala Karappan skin is hyperpigmented, erythemators, macular, slightly 
raised margenated with central clearing in nature. 
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5. Mozhi 
Examination of Mozhi includes clarity of speech, crying, low and high piched 
voice, slurring speech. 
No abnormalities were observed in Bala Karappan. 
 
6. Vizhi 
Pallor of the conjunctiva, conjunctivitis, cataract (any redness and pterygium 
etc.) 
No abnormality was seen in Bala Karappan. 
7. Malam 
Semisoild, colour, froth, abnormal consistency, frequency, constipation, foul 
smell etc,. 
In Bala Karappan constipation may be present. 
 
8. Moothiram 
Examination of urine for the determination of Neerkuri and Neikuri. It is one 
of the important diagnostic method. 
ePh;f;Fwp (Neerkuri) 
“te;j ePh; fhpnail kzk; Eiu vQ;rnyd; 
iwe;jpaYsit aiwFJ KiwNa” 
- Neha; ehly; Kjy; ghfk;      
ePhpy; epwk;> kzk;> Eiu> vil> vQ;ry;> Mfpatw;iw Nehf;f Ntz;Lk;.      
 
“Mbf;fyrj; jhtpNa fhJ nga; 
NjhUK$h;j;jf; fiyf;Fl;gL ePhpd; 
epwf;Fwp nea;Fwp epUkpj;jy; flNd” 
- Njud; 
 
Prior to the day of urine Examination the patient should have good sleep and 
instructed to take a balanced diet. After waking up in the morning, the first voiding 
urine is collected in a clear wide mouthed glass container and is subjected to analysis 
of “Neerkkuri” within 1½ hours. 
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Urine has the following general features 
 Niram 
 Edai 
 Manam 
 Nurai 
 Enjal 
 
nea;f;Fwp (Neikkuri): 
Foe;ijfspd; ehbeil rhpahf fzpg;gjpy; rpukk; cs;sjhy;> nea;f;Fwp 
ghpNrhjid %yk; Nehahsh; vf;Fw;wj;jhy; ghjpf;fg;gl;Ls;shh; vd;gjid 
fzpf;fyhk;. 
ghyf; fug;ghd; Nehahspapd; rpWePiu Nrhjid tl;bypy; Cw;wp 
xspkpFe;j ,lj;jpy; ePhpd; miyapy;yhj NghJ ey;nyz;nzaj;Jsp tp;l;L 
ghh;f;fg;gl;lJ. rpyhpy; muntd ePz;Lk Mop Nghy; (Nkhjpuk;) gutpAk;> rpyhpy; 
Kj;J Nghy; epd;Wk; fhzg;gl;lJ. 
“muntd ePz;bd; m/Nj thjk; 
MopNghw; gutpd; m/Nj gpj;jk; 
Kj;njhj;J epw;fpd; nkhoptnjd; fgNk”. 
- Neha; ehly; Kjy; ghfk 
“vz;nza; tpl;L ghu;f;Fk; tpjp 
epwf;Fwp Fiuj;j epUkhz ePupw; 
rpwf;f ntz;nza;Nahh; rpWJsp eLtpLj; 
dpd;wjptiy Nghk; newptpopawpTk; 
nrd;wJ GfOQ; nra;jpia AzNu”. 
 
The collected specimen (urine) is kept open in a glass dish or china clay 
container. It is to be examined under direct sunlight, without any shaking of the 
vessel. Then add one drop of gingelly oil without disturbing the urinary specimen and 
the NeiKuri was noted in direct sunlight and conclude the diagnosis as follows, 
 
Character of Vathaneer 
“Muntd ePz;bd/Nj thjNk”. 
When the oil drop lengthens like a snake, it is called “Vatha Neer” 
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Character of Pithaneer 
“Msp Nghw;gutpd; m/Nj gpj;jk;”. 
When the oil drop spreads like a ring, it is called “Pitha Neer” 
 
Character of Kabaneer 
“Kj;njhj;J epw;fpd; nkhoptnjd; fgNk”. 
When the oil drop appears like a pearl, it is called “Kaba Neer” 
 
Character of Thonthaneer 
Snake in the ring, ring in the snake, snake in the pearl and ring in the pearl are 
the characters of “Thontha Neer”. 
 
Types of land (Nilam) 
Nilam is classified into 5 types depending on the surrounding vegetation, 
landscape and ecological state study of 5 places is very much necessary as some 
diseases are common in particular land 
1. Kurinji - Mountain and its surroundings liver diseases and fluorosis are 
common. 
2. Mullai - Forest and its surroundings pitha noi and liver diseases are common. 
3. Marutham- Field and its surroundings. The ideal places for healthy living. 
4. Neithal - Sea and seashores.  Liver disease occurs in combination with other 
diseases. 
5. Paalai - Desert and its surroundings.Vatha, Pitha, Kabha, diseases occur.  
 
The disease Bala Karappan was predominant in Neithal nilam. 
Paruvakalam 
Siddhars have classified a year into six seasons each containing two tamizh 
months. 
1. Kaarkalam  - Avani & Purattasi (Aug 18 to Oct17) 
2. Koothirkamam - Ippasi & Karthika (Oct 18 to  Dec 15) 
3. Munpanikalam - Margazhi & Thai  (Dec 16 to Feb12) 
4. Pinpanikalam  - Masi & Panguni  (Feb 13 to Apr13) 
5. Elavanilkalam  - Sithirai & Vaigasi  (Apr15 to June14) 
6. Muthuvenilkalam - Aani & Aadi  (June15 to Aug15) 
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Udal Vanmai (Body Immunity) 
The vanmai is classified into three kinds. 
They are, 
1. IyarkaiVanmai- Natural immunity of the body caused by Mukkutram right from 
birth onwards. 
2. KalaVanmai- Development of immunity according to age and environment. 
3. SeyarkaiVanmai- Improving the health by intake of nutritients, food materials, 
exposure to some disease, activities and medicines. 
 
Udal thathukkal (Seven udal kattugal) 
Udal thathukkal General definition of each type 
Saram Gives strength to body and mind 
Seneer 
Responsible for knowledge, strength, boldness, healthy, 
complexion. 
Oon 
Gives structure and shape to body and is responsible for 
movements of the body 
Kozhuppu 
Lubricates the internal organs and helps the organs to 
Work smoothy. 
Enbu 
Protects the vital organs and act as basis for movements 
and maintains body structure. 
Moolai 
Present inside the bones and it gives strength and 
maintains the normal condition of the bone. 
Sukilam/ Suronitham Responsible for reproductive function 
 
Human body is made up of seven udal kattugal which are important for the 
structure and function of the body. Among the seven udal kattugal (seven physical 
constituents) saaram and seneer are commonly affected in bala karappan. 
Management of Bala Karappan in Siddha System 
“kpfpDk; FiwapDk; Neha;nra;Ak; EhNyhh; 
tspKjyh ntz;zpa %d;W”. 
- jpUf;Fws; 941  
In Siddha system the main aim of the treatment is to set right the derangement 
of mukkutram. Treatment is not only for perfect healing but also for prevention and 
rejuvenation. It is also very much essential to know the disease through its aetiology. 
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The nature and severity of the illness, the seasons and the time of occurance must be 
observed clearly. 
 
Line of treatment 
Line of treatment is as follows, 
a) Kaappu  (Prevention) 
b) Neekam (Treatment) 
c) Niraivu  (Restoration/Rejuvenation of wellbeing) 
1. Kaappu (Prevention of BalaKarappan) 
 Use warm water for bath 
 Take bath daily and avoid bathing in lake, pond. 
 Use green gram powder or “Nalangu Maa” instead of soap for bath. 
 Wash in dresses with disinfectant solution and dry in direct sunlight. 
 Prevent from Mosquito bite. 
 Advised to wear fresh dry and cotton clothes. 
 Advised to trim the nails  
 It is a good habit to wash hands after touching other people or animals. 
General instructions for Eczema patients 
 The patient should not scratch and keep his nails short. 
 The diet should be light. The exact composition of the diet depends upon the 
History of the patients, the diet habits and the results of the allergy test. 
 Allergic stuffs should be avoided. 
 Healthy hobbies and playing should be encouraged and speed up recover 
 
Neekam (Treatment) 
The aim of Neekam is based on 
 To bring the deranged three humours to equilibrium state. 
 To treat the patient with 
 Internal Medicine 
 External Medicine 
 Diet restictions 
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3. Niraivu (Rejuvenation) 
Physical, psychological, social and economic rehabilitation and reassurance of 
individuals is known as Niraivu. 
 Rest
 Positive mental attitude
 Life style modification
kUj;Jtk; 
    1. Ntw;Wepiy tsh;r;rpaile;j thjj;jpid jd;dpiyg;gLj;jNtz;Lk; 
    2. jd;dpiy tsh;r;rpaile;j Iaj;jpid rkg;gLj;jNtz;Lk; 
    3. gpj;jFw;wj;jhy; ghjpg;gile;Js;s thjj;jpidAk; rhpg;gLj;jNtz;Lk;. 
    4. td;ik ,oe;j clw ;fl;Lfis td;ik milar; nra;Ak ;tifapy; 
      kUe;jspf;fNtz;Lk;. 
Keeping in mind the need for bringing out an effective therapy for Bala 
Karappan from Siddha system of Medicine, the author has undergone this dissertation 
work with Saaranai ennai (Internal and Enternal Medicine). The dosage of Medicine 
all 6 – 12 years : 1-2 ml (int), 30ml(ext). 
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MODERN ASPECT 
SKIN ANATOMY 
 
INTRODUCTION 
The skin is composed of a superficial epithelial layer- the Epidermis, and an 
underlying connective tissue layer- the Dermis or Corium. Beneath the corium is 
another connective tissue layer- the Hypodermis or subcutaneous layer. It makes up 
16% of total body weight, with a surface area of 1.8m
2
. The thickness of skin varies 
from 0.5mm to 4.0mm. 
EPIDERMIS 
The mature Epidermis is formed of non-vascular stratified epithelial tissue 
composed of predominantly keratinocytes. The function of epidermis is protection of 
the organism from the external environment through physical, chemical, and 
immunologic barrier functions.  Its usual thickness is between 0.07mm and 0.12 mm. 
It is thickest on the palms of the hand and soles of the feet. The epidermis is mainly 
divisible into two main systems keratinizing or Malpighian system (Keratinocytes) 
which forms the bulk and the pigmentary system (Melanocytes) which produces the 
pigment. The epidermis consists of Squamous cells (Keratinocytes), Melanocytes 
(The pigment forming cells), Langerhans cells(Dentritic cells of the mononuclear 
phagocyte system). 
 
LAYERS OF EPIDERMIS 
 Stratum germinatum -This is the deepest portion of the epidermis and is 
composed of columnar cells placed perpendicular to the skin surface. The 
whole of the epidermis germinates from this stratum hence the name 
“stratum germinatum”. 
 Stratum malpigii– It is superficial to the basal cell layer and is composed of 
several layers of polyhedral cells connected to each other by intercellular 
bridges. 
 Stratum granulosum- It is superficial to stratum malpighii. It is composed of 
flat, fusiform cells which are one of the three layers. These cells contain 
irregular granules of Keratohyalin and lysosomal enzymes and cystine rich 
proteins. 
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 Stratum lucidum– It is superficial to the stratum granulosum. It is pale, 
wavy-looking layer known as stratum lucidum which is formed by many 
layers of flattened and closely packed cells. 
 Stratum corneum- This is the most superficial layer, the outer surface of skin 
which is exposed to the atmosphere. It is formed by many layers of non 
nucleated, flattened, cornified cells. 
 
DERMIS 
The dermis forms a tough, pliable, fibrous supporting structure between the 
epidermis and the subcutaneous fat. The thickness of the skin is 1-3 mm. It is 
profusely supplied with blood vessels. The connective tissue cells in the dermis are 
spindle shaped fibroblast that is responsible for the synthesis of collagen, elastic fibres 
and mucopolysaccharides. Phagacytic histocytes, mast cells and motile leukocytes are 
also present. Within the dermis blood vessels, lymphatics, neural structures, eccrine 
and apocrine sweat glands, hairfollicles, sebaceousglands and smooth muscle are 
present. Morphologically, the dermis can be divided into two layers, the superficial 
papillary layer that interdigitates with the reteridges of the epidermis and the deeper 
reticular layer that lies beneath the papillary dermis. The extracellular matrix of the 
dermis consists of collagen and elastic fibers embedded in an amorphous ground 
substance. Collagen provides strength and stability to the dermis, while elastic fibers 
allow for elasticity. 
 
SUBCUTANEOUS TISSUE 
The panniculus, or subcutaneous tissue, consists of fat cells and fibrous septa 
that divide it into lobules and anchor it to the underlying fascia and periosteum. Blood 
vessels and nerves are also present in this layer which serves as a storage depot for 
lipid, an insulator to conserve body heat, and a protective cushion against trauma. 
 
APPENDAGEAL STRUCTURES 
HAIR 
Hair follicles are distributed throughout the skin, except in the palms, soles, 
lips and glans penis. Individual follicles extend from the surface of the epidermis to 
the deep dermis.  
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The hair follicle is divided into four segments:  
 The infundibulum, which extends from the skin surface to the 
sebaceous duct. 
 The isthumus extending from the sebaceous duct opening to the bulge. 
 The lower follicle between the bulge and the hair bulb and  
 The hair bulb.  
The bulge is the insertion of the arrector pili muscle and is a focus epidermal 
stem cells. The bulb is where the matrix cells and dermal papilla are involved in 
formation and maintenance of the hair. Each hair follicle is lined by germinative cells, 
which produce keratin and melanocytes, which synthesis pigment. The hair shaft 
consists of an outer cuticle, a cortex of keratinocytes and an inner medulla. The root 
sheath which surrounds the hair bulb is composed of an outer and inner layer. Hair 
growth is under endocrine control. Hair grows about 1-2 cm per month. 
 
ANATOMY OF THE SKIN 
CROSS SECTION OF THE SKIN 
 
 
 
 
 
 
 
 
 
 
 
SEBACEOUS GLANDS 
Sebaceous glands occur in all areas except the palms, soles and dorsal feet and 
are most numerous on the face, upper chest and back. They are situated in upper half 
of the corium. Their ducts open into the hair follicles except on the lips, prepuce and 
labia minora, where they emerge directly onto the mucosal surface. These holocrine 
glands are saccular structures that are often branched and lobulated and consist of a 
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proliferative basal layer of small flat cells peripheral to the central mass of lipidized 
cells. The latter cells disintegrate as they move toward the duct and form the lipid 
secretion known as sebum, which consists of triglycerides, wax esters, squalene and 
cholesterol esters. The purpose of sebum production likely relates to hydrophobic skin 
carrier function. Sebaceous glands depend on hormonal stimulation and are activated 
by androgens by puberty. Fetal sebaceous glands are stimulated by maternal 
androgens and their lipid secretion, together with desquamated stratum corneum cells, 
constitutes the vernix caseosa. 
 
APOCRINE GLANDS 
The apocrine glands are located in the axillae, areolae, perianal, genital areas 
and the peri umbilical region. These large, coiled, tubular structures continuously 
secrete an odorless milky fluid that is discharged in response to adrenergic stimuli, 
usually as a result of emotional stress. Bacterial biotransformation of apocrine sweat 
components (fatty acids, thio alcohols and steroids) accounts for the unpleasant odour 
associated with perspiration. Apocrine glands remain dormant until puberty, when 
they enlarge and secretion begins in response to androgenic activity. The secretory 
coil of the gland consists of a single layer of cells enclosed by a layer of contractile 
myoepithelial cells. Although apocrine glands, do not function in thermo-regulation. 
They are involved in certain disease processes. 
 
ECCRINE SWEAT GLANDS 
Eccrine sweat glands are distributed over the entire body surface and are most 
abundant on the palms and soles. Those on the hairy skin respond to thermal stimuli 
and serve to regulate body temperature by delivering water to the skin surface for 
evaporation in contrast, sweat glands on the palms and soles, respond mainly to 
psychophysiologic stimuli. 
Each eccrine gland consists of secretory coil located in the reticular dermis or 
subcutaneous fat and a secretory duct that opens onto the skin surface. The glands are 
supplied by sympathetic nerve fibers, but the pharmacologic mediator of sweating is 
acetylcholine rather than epinephrine. Sweat from these glands consists of water, 
sodium, potassium, calcium, chloride, phosphorus, lactate and small quantities of iron, 
glucose and protein. The composition varies with the rate of sweating but is always 
hypotonic in normal children. 
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NAILS 
Nails are specialized protective epidermal structures that form convex 
translucent tight-fitting plates on the distal dorsal surfaces of the fingers and toes. The 
nail plate, which is derived from a metabolically active matrix of multiplying cells 
situated beneath the posterior nail fold, is composed of anucleate keratinocytes. Nail 
growth is relatively slow; complete finger nail regrowth takes 6 months, while 
complete toenail regrowth requires 12-18 months. The nail plate is bounded by the 
lateral and posterior nail folds; a thin eponychium(cuticle) protrudes from the 
posterior fold over a crescent-shaped white area called the lunula. The eponychium 
serves as a sealant barrier to protect the germinal matrix of the nail plate. Nail health 
relies on several factors, including nutrition, hydration, local infection/irritation and 
systemic disease. 
 
BLOOD VESSELS 
The cutaneous arteries arise directly or indirectly from the underlying source 
arteries forming anastomosis in the deepest part of the cortex. From here, single 
vessels run upwards and form a second network in the upper cortex. Finally teminal 
arterioles ascend into the papillae ending in capillary loops, which drain into 
connecting venules. The blood is returned to the large veins in the subcutaneous 
tissue. 
 
LYMPHATICS 
The skin contains a rich a network of lymphatics which drain into a few larger 
vessels in the hypodermis. 
 
NERVE SUPLY 
The nerve supply of skin consists of motor sympathetic portion derived from 
the symphathetic ganglia and sensory spinal portion arising from the dorsal root 
ganglia. The symphathetic fibre innervate the blood vessel, erector pilorum muscles 
and adrenergic and cause contraction. 
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FUNCTIONS OF THE SKIN 
Protective function 
The epidermis and  sub cutaneous fat play roles in the protective functions, the 
mechanical properties of the skin depends mainly on the dermis. It forms an effective 
barrier against microbial invasion and has properties of mechanical, chemical, atomic, 
thermal and phototic damage. 
Immunological function 
The skin is a dynamic organ that contains different cells which contains 
elements of the innate and adaptive immune system which are activated when the 
tissue is under attack by invading pathogens 
Sensory function 
The skin is richly supplied with nerves.  It has many nerve endings, which 
form the specialized cutaneous receptor which provide information regarding 
environmental changes to the brain. 
Secretion function 
Skin secretes sweat through sweat glands and sebum through sebaceous 
glands. By secreting sweat, skin regulates body temperature and water balance. 
Sebum keeps the skin smooth and moist. 
Excretion function 
Skin can excrete small quantities of waste materials like urea, salts and fatty 
substance. 
Synthesis of vitamin-D 
UV rays act on the skin to form Vit D3, activated in liver and kidneys, active 
form then acts on the intestines to increase calcium and phosphate absorption and on 
bone to increase calcium and phosphate mobilization. 
 Body heat regulation 
  Skin plays an important role in the regulation of body temperature. Excess 
heat is lost from body through skin by radiation, conduction, convection and 
evaporation. Sweat glands of the skin play active part in heat loss by secreting sweat. 
The lipid content of sebum prevents loss of heat from the body in cold environment.  
 Regulation of water and electrolyte balance 
  Skin regulates water balance and electrolyte balance by excreting water and 
salts through sweat. 
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Storage function of skin 
Skin stores fat, water, chloride and sugar. It can also store blood by the 
dilatation of the cutaneous blood vessels 
Absorption 
Skin can absorb the fat soluble substances and some ointments 
Gaseous exchange through skin 
A small amount of gaseous exchange occurs through the skin, the amount of 
co2 exchanged through the skin is negligible compared to the amount exhaled from the 
lungs. 
Pigment of skin 
Melanin pigment protects the skin from the harmful effects of ultraviolet rays. 
 
ATOPIC DERMATITIS (or) ATOPIC ECZEMA 
 
The signs and symptoms of “Bala karappan” are closely similar to signs and 
symptoms of Atopic Dermatitis (AD). Atopic dermatitis (AD) or eczema is the most 
common chronic relapsing skin disease seen in infancy and childhood. It affects 10-
30% of the children worldwide and frequently occurs in families with other atopic 
disease such as asthma allergic rhinitis, and food allergy. Infants with Atopic 
dermatitis are predisposed to development of allergic rhinitis and asthma later in 
childhood. A process called “the atopic march”.  
 
DEFINITION 
Atopic dermatitis is an inflammatory skin disorder characterized by erythema, 
edema, intense pruritis, exudation, crusting and scaling. 
 
EPIDEMIOLOGY 
The prevalence of Atopic dermatitis has increased over the past 30 years. It is 
currently estimated that 10-20% of children and 1-3% of adults in developed countries 
in within are affected by the disorder. Atopic dermatitis often starts in early infancy, 
approximately 45% of all cases begin within the first 6 months of life 60% during the 
first year and 85 % before 5 years of age upto 70% of these children outgrow the 
disorder before the adolescence. Children with atopic dermatitis are at high risk of 
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developing asthma and allergic rhinitis of those who will develop Atopic dermatitis 
before the age 2, 50% will develop asthma during subsequent years. The prevalence 
of eczema is on the increase and currently affects 12- 15% of all school age children. 
 
 Aetiology 
Atopic dermatitis is a complex genetic disorder that results in a 
 Defective skin barrier 
 Reduced skin innate immune response 
 Exaggerated T-cell response to environment allergens and microbes that lead 
to chronic skin inflammation. 
 
Pathology 
Acute Atopic dermatitis skin lesions are characterised by spongiosis or marked 
intercellular oedema of the epidermis. Antigen presenting cells (APCs) in the 
epidermis, such as langerhans cells (LCs) exhibit surface bound immunoglobulin 
(IgE) molecues. 
These ACPs play an important role in cutaeous allergen presenting to T helper 
type 2 (Th2) cells. There is a marked perivenular T-cells infiltrate with occasional 
monocyte- macrophages in acute Atopic dermatitis lesions. Mast cells are found in 
normal numbers but in different stages of degranulation. 
Chronic lichenified Atopic dermatitis is characterized by a hyperplasic 
epidermis with hyperkeratosis, and minimal spongiosis. There are predominantly IgE- 
bearing LCs in the epidermis, and macrophages in the dermis. Mast cell and 
eosinophil numbers are increased Eosinophil contribute to allergic inflammation by 
secreting cytokines and mediators that augment inflammatory responses and induce 
tissue injury in Atopic dermatitis through the production of reactive oxygen 
intermediates and release of toxic granule proteins. 
 
Pathogenesis 
Two forms of Atopic dermatitis have been identified 
1) Atopic eczema is associated with IgE mediated sensitization and occurs in 70-
80% of patients with Atopic dermatitis 
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2) Non atopic dermatitis is not associated with IgE mediated sensitization and is 
seen in 20-30% of patients with Atopic dermatitis. Both forms of Atopic 
dermatitis are associated with eosinophilia. 
In atopic eczema circulating T cells expressing the skin homing receptor 
cutaneous lymphocyte – associated antigen (CLA) produced increased levels of the 2 
cytokines, interleukin (IL-4) and another cytokine IL-5 plays an important role in 
eosinophil development. 
Non atopic eczema is associated with lower IL-4 and IL-3 production than in 
atopic eczema. The developement of AD skin lesion is orchestrated by local tissue 
expression of pro inflammatory cytokines and chemokines. Cytokines such as tumour 
necrosis factor   (TNF- ) and IL -1 from keratinocytes, mast cells and dendritic cells 
bind the receptor on vasular endothelium. 
These events proceed from tethering activation and adhesion to the endothelium, 
followed by extravasation of inflammatory cells. Once the inflammatory cells 
infiltrate the tissue, they respond to chemotactic gradients established by chemokines, 
released at sites of injury or infection. Chemokines plays a central role in defining the 
nature of the inflammatory infiltrate in Atopic dermatitis. Other c-c chemokines, 
monocytes, chemotactic protein -4 (MCP -4) exotaxin, macrophage-derived 
chemokines (MDC) are increased in Atopic dermatitis. Elevated IL-5 and GM/CSF of 
eosinophils and monocyte – macrophages as well as LCs. 
In healthy people the skin acts as a protective barrier against external irritants, 
moisture loss and infection. Proper function of the skin depends on adequate moisture 
and lipid content, functional immune responses and structural integrity. Several dry-
skin is a hallmark of atpoic dermatitis. 
This is a result of compromise of physical and chemical structures of the 
epidermal barrier, which leads to excess transepidermal water loss. Filaggrin a 
component of the cytoskeleton and its breakdown products are critical to skin barrier 
function. Genetic mutations in the filaggrin gene family have been identified in up to 
50% severe patients with Atopic dermatitis. Such patients have increased risk of 
bacterial, viral and fungal infection related to impairment of innate immunity, 
including a loss of barrier and impaired generation of antimicrobial peptides. 
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Potential Atopic dermatitis triggers: 
Associated with food: 
 Food allergens found in cow’s milk, eggs, peanuts 
 Tree nuts (eg. walnuts, cashews) Soya, wheat, fish, shelfish 
Associated with direct contact 
 Toiletries contacting alcohol, astringents, or fragrances harsh detergents/soaps  
 Abrasive clothing (wool or synthetics) 
Associated with physiologic /emotional stressor 
 Infections (Especially from over heating/sweating) 
 Psychological stress 
 Other factors   
 Irritants - physical, chemical or electrical 
 Sensitizers - plants, clothings, cosmetics, infections, diet and focal sepsis 
 External infections - streptococci, staphylococci, fungus. 
 Internal septic focus shedding toxins or causing bacteraemia. 
 Diathesis   - Allergic, xerodermic, hyperhidrotic or seborrhoeic 
 Drugs   - given for the diseaes or otherwise 
 State of local or general nutrition 
 Climate  - Temperature and humidity 
 
Clinical manifestations 
Atopic dermatitis typically begins in infancy, 50% of patients experience   
symptoms in the 1 st yr of life & additional 30% all diagnosed between 1-5 yr of age. 
 
Cardinal features of Atopic dermatitis are 
In acute stage: 
Intense pruritic with erythematic papular lesions. 
In subacute stage: 
            Erythematous Excoriated, scaling papular lesion. 
In chronic stage: 
Lichenification or thickening of skin with accentuated surface markings 
and fibrotic papular (prurigo nodularis). In chronic Atopic dermatitis all three 
types of reactions may coexist in same individual. 
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Acute Atopic dermatitis in infants 
 Extensor surface of extremities, face (forehead, cheeks) 
 Neck, scalp, trunk 
Chronic Atopic dermatitis in childhood (2 years to puberty) 
 Flexual surface of extermities 
 Neck, wrist, ankles 
 
Clinical Features of Atopic dermatitis 
Major features 
 Pruritis, personal or family history of Atopic dermatitis 
 Facial and extensor eczema in infants and children. 
 Chronic or relapsing dermatitis 
 
Associated Features 
 Xerosis, keratosis, ichthyosis, palmar hyper linearity 
 Cutaneous infections(staphylococcus, herpes simplex, moliuscum warts) 
 Non specific dermatitis of the hands or feet 
 White dermagraphism, Early age at onset 
 Elevated serum Ig E levels, Facial erythema or pallor 
 Positive results of immediate type allergy skin test 
 Course influenced by environment \emotional factors 
 
Lab Findings 
 No specific Laboratory tests to diagnose Atopic dermatitis 
 Peripheral blood eosinophilia 
 Increased serum Ig E levels 
 Prick skin test to identify the allergen. 
 
Differential Diagnosis of Atopic Dermatitis 
Infections and infestations 
 Scabies, Dermatophytosis 
 HIV associated dermatitis, Insect bites. 
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Congenital Disorders 
 Familial keratosis pilaris 
 Netherton syndrome 
Chronic dermatomes 
 Seborrheic dermatitis, contact dermatitis 
 Nummular dermatitis 
 Psoriasis dermatitis, ichthyosis dermatitis 
Auto immune disorder 
 Dermatitis herpetiformis 
 Pemphigus foliaccus, Hyper IgE syndrome 
Metabolic disorder 
 Zinc deficiency, Pyridoxin, niacin, Phenyl ketonuria 
 
TREATMENT 
          The Treatment of Atopic deramtitis requires a systematic multifaceted approach 
that incorporates – Skin hydration 
                         Topical anti inflammatory therapy 
                          Identification and elimination of flare factors 
                          Systemic therapy 
 
Categorization of physical severity of Atopic dermatitis 
       Clear - Normal skin with no evidence of Atopic dermatitis 
       Mild - Area of dry skin in frequent itching (with or without redness) 
       Moderate - Area of dry skin infrequent itching redness (with or without 
excoriation and localised skin thickening) 
Severe - Widespread area of dry skin incessant itching, Redness (with or 
without excoriation, extensive skin thickening, bleeding, oozing, 
cracking and alteration of pigmentation) 
 
Life style changes and general treatments for Atopic dermatitis 
 Avoiding hot tubs, steam baths and chlorinated swimming pools 
 Avoiding scratchy clothes, getting skin patch test 
 Minimizing skin dryness by using lotion specifically designed for sensitive 
skin, drinking plenty of fluids 
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 Preventing flare- ups by avoiding exposure to the specific allergen or allergens 
that induce the condition 
 Using ice bags or cool wet compresses to help relieve itching and 
inflammation, using mild soaps and not over harshly scrubbing skin. 
Prick Test 
Prick test are a way of detectimg cutaneous typr I (immediate) hypersensitivity 
to various antigens such as pollen, house dust mite or dander. 
Patch test detect type IV (delayed or cell- mediated) hypersensitivity 
It is common practice for a battery of around 20 common antigens, including 
common sensitizers such as nicke, rubber and fragrance mix to be applied to the skin 
of the back under aluminium discs for 48 hours. The sites are then examined for a 
positive reaction 24 hours later and again a further 2 hours later. The positive test is 
revealed by the development of an eczematous patch with erythematic swelling and 
vesicles at the site of application. 
Patch Test reaction is graded in the following degrees 
        +            - Only redness 
        ++          - Marked redness and swelling 
        +++        - Marked redness, swelling and papules 
        ++++      - Redness, oedema and vesicles 
Specific IgE levels to antigens can be measured in serum by a specific radio 
allergic sorbent test (RAST). These are occasionally performed to support diagnosis 
of Atopic eczema and to determine specific environment allergens, eg. Pet dander, 
horse hair, house dust mite, pollens and foods. 
 
Bacterial and viral swabs for microscopy and culture 
These are useful tests in suspected secondary infection. Skin swabs for 
bacteriology assessment will invariably reveal the presence of bacteria. In the case of 
recurrent impetigo in a child with atopic eczema, bacterial swabs should be taken 
from carrier sites (axillae and groin) from both the affected individual and house hold 
members. 
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Prognosis of Atopic dermatitis 
Dermatitis and Eczema are as rule curable conditions. Dermatitis is mostly 
non-infective and they do not leave scars. The patient needs reassurance of these 
points. It must be remembered that epidermis is an ectodermic structure and so takes 
time to heal. 
Acute eczema heals readly in about 1-4 weeks with treatment. Chronic 
eczemas in which anatomical and functional changes set in, take time to disappear. 
Disseminated and generalised eczemas are not only slow to heal, but are 
accompanined by ill health. 
Infantile and Atopic eczema are troublesome and uncomfortable. The former 
lates till the age of twenty five or even though life. Its course is marked by 
spontaneous remissions and exacerbations. Psychogenic stresses, climate extremes 
and poor health aggravate eczema. The cure of these conditions is restarted in tropical 
countries by heat, humidity and the prevalent unhygienic condition.  
 
40 
 
TRIAL DRUG – SAARANAI ENNAI 
 
 
Saaranai ennai (SE) 
 
             
 
“                  
                    
                  
               
                        
                 
                  
                             
                         
          ”. 
 
Usage : Internal and external medcine 
Ref : Pillaipini Maruthuvam, Pg.no: 522, 571 
Author: A.Sundarasan,B.I.M. 
 
SOURCE OF RAW DRUGS: 
The drug Uthamani ver, mudakothan ver, siria Vazhuthalai ver, Yerukku ver, 
murungai ver, pungan ver was collected from my native place, Thiruvannamalai. And 
other required raw drug were procured from a well reputed indigenous drug shop 
from Paris town, Chennai. All raw drugs were Authenticated by the Pharmacognosist, 
Department of Medicinal Botany, GSMC, Chennai. 
PURIFICATION OF RAW DRUGS: 
Raw drugs are purified as mentioned in Sikicharathna deepam sarakku suthi 
muraigal. 
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INGREDIENTS: 
1. Saaranai ver (Trianthema decandra) 
2. Uthamani ver (Pergularia daemia) 
3. Mudakothan ver (Cardiospermum halicacabum) 
4. Siria vazhuthalai ver (Solanum  melongena) 
5. Yerukku ver (Calotrophia gigantia) 
6. Murungai ver (Moringa olifera) 
7. Pungan ver (Pongamia pinnata) 
8. Kalarchi (Caesalpinia bonduc) 
9. Milagu (Piper nigrum) 
10. Ulli (Allium sativum) 
11. Bootha karappan pattai (Sterculia foetida) 
12. Vasambu (Acorus calamus) 
13. Amanakku ennai (Ricinus communis) 
 
TRIAL MEDICINE INGREDIENTS 
        
                               Pergularia daemia                                 Ricinus communis 
        
                      Caesalpinia bonduc                                   Acorus calamus 
        
                       Solanum  melongena                               Allium sativum 
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     Cardiospermum halicacabum                    Pongamia pinnata 
 
          
                    Trianthema decandra                              Calotrophia gigantia 
 
         
                              Piper nigrum                                    Moringa olifera 
 
 
Sterculia foetida 
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PREPARATION AND PROPERTIES OF TRIAL DRUGS 
METHOD OF PREPARATION 
 
PREPARATION: 
 All the above drugs were purified. The purified drugs were made into fine 
powder, ground with water and made into paste. The paste was mixed with the castor 
oil and allowed to boil until it reaches the manal patham for external and mezhugu 
patham for internal medicine. 
DRUG STORAGE: 
 The trial drug saaranai ennai stored in air tight container internally and 
externally separately. And it is dispensed to the patients. 
 Dosage -  Internally  : 1-2ml 
           Externally  : 30ml 
 Duration  - 21 days 
 Indication  - Karappan  
PROPERTIES OF TRIAL DRUG: 
1. SAARANAI VER 
Botanical name : Trianthema decandra 
English name : Spreading hog weeds 
Family : Aizoaceae 
Organoleptic characters 
Taste : Kaippu  
Potency : Veppam 
Division : Karppu 
Chemical constituents : Trianthimine flavonoid, Alkaloid, 
 Tetraterpenoid. 
Action                      : Expectorant, Laxative, Anti – microbial, Anti- 
 histamine. 
Pothu gunam      
“                          
                  –      
                                  
                ”. 
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2. UTHTHAMANI VER 
Botanical name : Pergularia daemia 
English name : Dog’s bane white low plant 
Family : Asclepidaceae 
Organoleptic characters 
Taste : Kaippu  
Potency : Veppam 
Division : Karppu 
Chemical constituents : Saponin, Steroid, Alkaloids, Triterpenes, 
 Cardenolides, Carbohydrates. 
Action : Anthelmintic, Anti-inflammatory, Anti- 
  bacterial, Anti-fungal 
Pothu gunam      
“                              
                        
                          
                      ”. 
-               
 
3. MUDAKKOTHTHAAN VER  
Botanical name : Cardiospermum halicacabum 
English name : Ballon vine; Heart pea or Winter cherry 
Family : Sapindaceae 
Organoleptic characters 
Taste : Kaippu 
Potency : Thatpam 
Division : Kaarppu 
Chemical constituent : Calycosin, Guercetin, Hentriacontunol,       
 Saponin, Essential oil, Rutin, Apigenin, 
 Protocatchuic acid, Pentadecanoie acid, 
 Protocatechualdehyde. 
Action : Anti – inflammatory, Anti – oxidant, Laxative, 
 Stomachic. 
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Pothu gunam 
“                              
                       –      
                           
                   ”. 
 
4. SIRIYA VAZHUTHALAI VER 
Botanical name : Solanum melongena 
English name : Eggplant, Brinjal 
Family : Solanaceae 
Organoleptic characters 
Taste : Kaippu, Thuvarppu 
Potency : Veppam 
Division : Kaarppu 
Chemical constituents  : Flavonoids, Tannins, Glycosides, Steroids, 
  Alkalods, Saponin. 
Action  : Anti-inflammatory, Anti-oxidant,  
  Stimulant, Hypnotic, Expectorant. 
Pothu gunam 
“                       
                      ”. 
-              
“                           
                      –        
                        
                  ”. 
-             
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5. ERUKKU VER 
Botanical name : Calotropis gigantea 
English name : Mudar, Gigantic swallow wood 
Family : Asclepidaceae 
Organoleptic characters 
Taste : Kaippu, kaarppu, madhuram 
Potency : Veppam 
Division : Kaarppu 
Chemical constituents : Methyl-β-carboline, carboxylate, 
 dehydrovomifoliol, pleurone, calotropogenin, 
 calotoxin, giganteol. 
Action : Anthelmentic, stimulant, tonic, diaphoretic, 
 febrifuge, emetic, alterative, laxative, Anti-
 histamine, Anti-microbial 
Pothu gunam 
“                                
                      –          
                        
                 ”. 
-             
 
6. MURUNGAI VER 
Botanical name : Moringa oleifera 
English name : Horse radish, drum stick tree 
Family : Moringaceae 
Organoleptic characters 
Taste : Kaippu, thuvarppu, inippu 
Potency : Thatpam 
Division : Kaarppu 
Chemical constituents : White Crystalline Alkaloids, Myristic Acid, 
 Mucilage, Gum resins, Phytosterol, 
 Moringine. 
47 
 
Action : Stimulant, Expectorant, Diuretic, 
 Antispasmodic, Tonic, Anti –inflammatory, 
 anti-histamine. 
Pothu gunam 
 “                              
                        –         
                             
                  ”. 
-               
“                            
                            ”. 
-                
 
7. PUNGAN VER 
Botanical name :  Pongamia pinnata 
English name : Karanka 
Family : Papilionaceae 
Organoleptic characters 
Taste : Kaippu, thuvarppu 
Potency : Veppam 
Division : Kaarppu 
Chemical constituents :  Pongamol, Pongagalabrone, Pinnatin, 
 Pongapin. 
Action : Astringent, Alterative parasiticide, Antiseptic, 
 Stimulant, Anti – inflammatory. 
Pothu gunam 
“                          
                         –       
                                 
                     ”. 
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8. KAZHARCHI 
         Botanical name : Caesalpinia bonduc 
English name : Bonduc nut, physic nut, moloucca bead. 
Family : Fabaceae 
Organoleptic characters 
Taste : Kaippu 
Potency : Veppam 
Division : Kaarppu 
Chemical constituents : Homoisoflavanoids, Caesalpinianone, 6-0-
 methylcaesalpinianone, Glutathione- s –
 transferase. 
Action   Antiperiodic, Antispasmodic, Tonic, 
 Anthelmintic, Febrifuge, Deobstructent, Anti – 
 Oxidant, Anti-Microbial. 
Pothu gunam 
“                          
                 –       
                          
                ”. 
 
9. MILAGU 
Botanical name : Piper nigrum 
English name : Black pepper 
Family : Piperaceae 
Organoleptic characters 
Taste : Kaippu, kaarppu 
Potency : Veppam 
Division : Kaarppu 
Chemical constituents : Alkaloids, Chavicine, Piperine, Piperidine, 
 Piperetin, Volatile oil, Caryophyllene. 
Action : Acrid, Carminative, Antiperiodic, Stimulent, 
 Resolvent, Antivatha, Antidote, Anti – 
 histamine, Anti –oxidant, Anti- bacterial. 
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Pothu gunam 
“                        
                       –       
                                
                      ”. 
-           
   
10. ULLI 
Botanical name : Allium sativum 
English name : Garlic 
Family : Liliaceae 
Organoleptic characters 
Taste : Kaarppu 
Potency : Veppam 
Division : Kaarppu 
Chemical constituents : Allixin, Methyl allyl disulphide, S-allyl 
 cysteine, Alliin, Allicin 
Action : Carminative, Stomachic, Tonic, Alterative, 
 Stimulant, Expectorant, Diuretic, 
 Anthelmintic, Anti – histamine, Anti- 
 microbial 
Pothu gunam 
                           
                    –      ! 
                               
                   . 
     
11. BOOTHAKARAPPAAN PATTAI 
Botanical name : Sterculia foetida 
English name : Poon tree, pinari 
Family : Sterculiaceae 
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Organoleptic characters 
Taste : Kaippu 
Potency : Veppam 
Division : Kaarppu 
Chemical constituents : Flavanoids, Phenylpropanoids, Alkaloids, 
 Terpenoids 
Action : Laxative, Diuretics, Diaphoretic, Anti – 
 inflammatory, Anti- Histamine 
Pothu gunam 
                        
                       –      
                         
                    . 
-               
 
12. VASAMBU 
Botanical name : Acorus calamus 
English name : Sweet-Flag 
Family : Araceae 
Organoleptic characters 
Taste : Kaarppu 
Potency : Veppam 
Division : Kaarppu 
Chemical constituents : Acorin, Calamin, Steroids, Glycosides 
Action                     :  Stimulant, Stomachic, Anti pesticide, 
 Carminative, Diuretic, Disinfectant, 
 Germicide, Anti –inflammatory 
Pothu gunam 
                                
                                 
                              
                               
-             
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13. AAMANAKKU 
Botanical name : Ricinus communis 
English name : Castor-oil plant. 
Family : Euphorbiaceae 
Organoleptic characters 
Taste : Kaippu 
Potency : Veppam 
Division : Kaarppu 
Chemical constituents : Glycerides, Ricinoleic, isoricinoleic, 
 dihydrocystearic acids, lipases, alkaloid, ricine 
Action  : Laxative, Emollient, Antivatha, Laxative, 
 Stimulant, Anti inflammatory 
Pothu gunam 
                        
                   . 
-            
                             
                  –          
                             
                    
-               
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PRE-CLINICAL SAFETY STUDIES 
BIO CHEMICAL ANALYSIS 
 
Preparation of sodium carbonate extract 
 2 gm of Saaranai ennai sample is mixed with 5gm of sodium carbonate and 
taken in a 100 ml beaker and 20 ml of distilled water is added. The solution is boiled 
for 10 minutes, cooled and then filtered. The filtrate is called sodium carbonate 
extract. 
 
S. No. EXPERIMENT OBSERVATION INFERENCE 
TEST FOR ACID RADICALS 
1. A. Test for sulphate: 
2ml of the above prepared extract 
is taken in a test tube.to this add 
2ml of 4% Ammonium oxalate 
solution. 
Absence of white 
precipitate 
Absent 
B. 2ml of extract is added with 2ml 
of dilute Hydrochloric acid until 
the effervescence ceases off. 
Then 2ml Barium chloride 
solution is added. 
Absence of white 
precipitate 
Absent 
2.  Test for chloride : 
2ml of extract is added with 
dilute Nitric acid till the 
effervescence ceases. Then 2ml 
of silver nitrate solution is added. 
Presence of white 
precipitate 
Present 
3.  Test for phosphate: 
2 ml of the extract is treated with 
2 ml of Ammonium molybdate 
solution and 2 ml of concentrated 
nitric acid. 
Absence of  Yellow 
precipitate 
Absent 
4.  Test for carbonate: 
2 ml of the extract is treated with 
2 ml of Magnesium sulphate 
solution. 
Absence of white 
precipitate 
 
 
Absent 
5.  Test for sulphide: 
1 gm of the substance is treated 
with 2 ml of concentrated 
Hydrochloric acid. 
Absence of  Rotten 
egg smelling 
Absent 
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6.  Test for Fluoride and 
oxalate : 
2ml of extract is added with 
dilute Acetic acid and 2 ml of 
Calcium chloride solution and 
heated. 
Absence of white 
precipitate 
 
 
Absent 
7.  Test for Borate : 
2 pinches of the substance is 
made into paste by using 
Sulphuric acid and alcohol 
(95%) and introduced into the 
blue flame. 
Absence of Green 
tinged flame 
Absent 
TEST  FOR BASIC RADICALS 
8.  Test for lead: 
2 ml of the extract is added 
with 2 ml of Potassium iodide 
solution. 
Absence of  Yellow 
precipitate 
Absent 
9.  Test for copper: 
One pinch of substance is made 
into paste with concentrated 
Hydrochloric acid in a watch 
glass and introduced into the 
non-luminous part of the flame. 
Absence of  Bluish 
green colored flame 
Absent 
10.  Test for aluminium: 
To the 2 ml of extract Sodium 
hydroxide solution is added in 
drops in excess. 
Absence of white 
precipitate 
 
 
Absent 
11.  Test for iron: 
To the 2 ml of extract 2ml of 
Ammonium thiocyanate 
solution and 2ml of 
concentrated Nitric acid is 
added. 
Presence of Blood 
red colour 
Present 
12.  Test for zinc: 
To the 2 ml of extract Sodium 
hydroxide solution is added in 
drops in excess. 
Absence of green 
tinged flame. 
Absent 
13.  Test for calcium: 
To the 2 ml of extract 
Ammonium oxalate solution 
solution is added. 
Absence of white 
precipitate 
 
 
Absent 
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14.  Test for magnesium: 
To the 2 ml of extract Sodium 
hydroxide solution is added in 
drops in excess. 
Absence of white 
precipitate 
 
 
Absent 
15.  Test for ammonium: 
To the 2 ml of extract few ml of 
Nessler’s reagent and excess of 
Sodium hydroxide solution are 
added. 
Absence of white 
precipitate 
 
 
Absent 
16.  Test for sodium: 
2 pinches of the substance is 
made into paste by using 
Hydrochloric acid and 
introduced into the blue flame 
Absence of white 
precipitate 
 
 
Absent 
17.  Test for mercury: 
2 ml of extract is treated with 
2ml of Sodium hydroxide 
solution. 
Absence of  Yellow 
precipitate 
Absent 
18.  Test for arsenic: 
2 ml of extract is treated with 
2ml of Silver nitrate solution. 
Absence of white 
precipitate 
 
Absent 
19.  Test for starch: 
2 ml of extracts treated with 
weak iodine solution. 
Absence of white 
precipitate 
 
 
Absent 
20.  Test for reducing sugar 
5ml of Benedicts qualitative 
solution is taken in a test tube 
and allowed to boil for 2 
minutes and added 10 drops of 
the extract and again boiled for 
2minutes.The colour changes 
are noted. 
Absence of white 
precipitate 
 
 
Absent 
21.  Test for alkaloids : 
2 ml of the extract is treated 
with 2ml of Potassium iodide 
solution. 
Absence of white 
precipitate 
 
 
Absent 
 
RESULT 
The given sample Saaranai ennai contains Chloride, Iron 
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PHYTOCHEMICAL ANALYSIS 
 
Project Report 
 
Project ID  NRS/AS/0338/02/2019 
Name and Address of the 
Researcher 
Dr.T.Swathini 
Government Siddha Medical College, 
Chennai 
Tamil Nadu, India 
Sample –ID SaaranaiEnnai - SE 
 
PHYTOCHEMICAL ANALYSIS 
Test for alkaloids: 
Mayer's Test: To the test sample, 2ml of mayer's reagent was added, a dull 
white precipitate revealed the presence of alkaloids. 
Test for coumarins:  
To the test sample, 1 ml of 10% sodium hydroxide was added. The presence of 
coumarins is indicated by the formation of yellow color. 
Test for saponins:  
To the test sample, 5 ml of water was added and the tube was shaken 
vigorously. Copious lather formation indicates the presence of Saponins. 
Test for tannins:  
  To the test sample, ferric chloride was added, formation of a dark blue or 
greenish black color showed the presence of tannins. 
Test for glycosides- Borntrager’s Test 
Test drug is hydrolysed with concentrated hydrochloric acid for 2 hours on a 
water bath, filtered and the hydrolysate is subjected to the following tests. To 2 ml of 
filtered hydrolysate, 3 ml of choloroform is added and shaken, choloroform layer is 
separated and 10% ammomia solution is added to it. Pink colour indicates presence of 
glycosides. 
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Test for flavonoids: 
To the test sample about 5 ml of dilute ammonia solution were been added 
followed by addition of few drops of conc. Sulfuric acid. Appearance of yellow color 
indicates the presence of Flavonoids. 
Test for phenols: 
Lead acetate test: To the test sample; 3 ml of 10% lead acetate solution was 
added.  A bulky white precipitate indicated the presence of phenolic compounds. 
Test for steroids: 
To the test sample, 2ml of chloroform was added with few drops of conc. 
Sulphuric acid (3ml), and shaken well. The upper layer in the test tube was turns into 
red and sulphuric acid layer showed yellow with green fluorescence. It showed the 
presence of steroids. 
Triterpenoids 
Liebermann–Burchard test: To the chloroform solution, few drops of acetic 
anhydride was added then mixed well. 1 ml concentrated sulphuric acid was added 
from the sides of the test tube, appearance of red ring indicates the presence of 
triterpenoids. 
Test for Cyanins 
A. Aanthocyanin: 
To the test sample, 1 ml of 2N sodium hydroxide was added and heated for 5 
min at 100ᵒC. Formation of bluish green colour indicates the presence of anthocyanin. 
Test for Carbohydrates - Benedict’s test 
To the test sample about 0.5 ml of Benedic’s reagent is added. The mixture is 
heated on a boiling water bath for 2 minutes. A characteristic coloured precipitate 
indicates the presence of sugar. 
Proteins (Biuret Test) 
To extracts 1% solution of copper sulphate was added followed by 5% 
solution of sodium hydroxide, formation of violet purple colour indicates the presence 
of proteins. 
Reference 
Brain KR, Turner TD. The Practical Evaluation of Phytopharmaceuticals. Bristol: 
Wright Scientechnica; 1975:36-45 
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RESULTS 
 
Test for Alkaloids, Flavonoids, Glycosides, Steroids and Triterpenoids 
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Test for Coumarins, Phenol, Tanins, Saponin and Protein 
 
 
 
Test for Cyanin and carbohydrates 
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PHYSICOCHEMICAL EVALUATION REPORT 
 
 
Project ID  NRS/AS/0338/02/2019 
Name and Address of the Researcher Dr.T.Swathini 
Government Siddha Medical College, 
Chennai 
Tamil Nadu, India 
Sample –ID SaaranaiEnnai – SE 
 
Sample Description 
 
 
State Liquid 
Appearance Reddish Brown 
Odour Aromatic 
Nature Dense viscous 
 
Determination of Iodine value  
About 20 gm of test sample was transferred into Iodine flask. To which 10 ml 
of chloroform was added and warmed slightly and cooled for 10 minutes. Followed 
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by this about 25 ml of Wiji’s solution was added in the same flask and shaken well. 
The flask was allowed to stand for 30 mins and refrigerated for anhour.T About 10 ml 
of KI solution was added to this and titrated against 0.1 N Sodium thiosulphate 
solutions until the appearance of yellow colour. 1 ml of starch indicator was added 
and again titrated against the sodium thiosulphate solution from the burette. 
Disappearance of blue colour indicates end point. Repeat the above procedure without 
taking sample and note the corresponding reading for blank titration. 
Determination of saponification value  
About 2 gm of test sample was transferred into the round bottomed flask. To 
this about 20 ml of 0.5 N alcoholic KOH solutions was added to the round bottomed 
flask. Repeatthe same procedure with out taking the sample for blank titration . 
Reflux both sample and blank round bottomed flasks for 1 hour. After reflux, allow 
both the round bottomed flasks to cool. Titrate the samples using 0.5 N HCl with 
phenolphthalein indicator. The disappearance of pink indicates the end point.  
Determination of Viscosity value  
Viscosity determination were been carried out using Ostwald viscometers. 
Measurement of viscosity involves thedetermination of the time required for a given 
volume ofliquid to flow through a capillary.The liquid is added to the viscometer, 
pulled into the upper reservoir by suction, and then allowed to drain by gravity back 
into the lower reservoir. The time that it takes for the liquid to pass between 
twoetched marks, one above and one bellow the upper reservoir, is measured. 
Determination of Refractive Index 
Determination of RL was carried out using Refractometer. 
Determination of Weight per ml 
 Weight per ml was determined using the comparative weight calibration 
method, in which the weight of 1ml of the base of the formulation was calculated and 
then weight of 1 ml of finished formulation were been calculated. The difference 
between weight variations of the base with respect to finished formulation calculated 
as an index of weight per ml. 
Acid Value 
Accurately 5 g of test sample was weighed and transferred into a 250 mL 
conical flask. To this, a 50 mL of neutralized alcohol solution was added. This 
mixture was heated for 10 min by heating mantle. Afterwards, the solution was taken 
out after 10 min and 1 or 2 drops of phenolphthalein indicator was added. This 
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solution was titrated against KOH solution from the burette. The appearance of pink 
color indicated the end point. The volume of consumed KOH solution was determined 
and the titration of test sample was carried out in triplicate and the mean of the 
successive readings was used to calculate the acid-value of the respective sample by 
following expression. 
Acid value = Titter Value X 0.00561X 1000 / Wt of test sample (g) 
Peroxide value 
5 g of the substance being examined, accurately weighed, into a 250-ml glass-
stoppered conical flask, add 30 ml of a mixture of 3 volumes of glacial acetic acid and 
2 volumes of chloroform, swirl until dissolved and add 0.5ml volumes of saturated 
potassium iodide soluton. Allow to stand for exactly 1 minute, with occasional 
shaking, add 30 ml of water and titrate gradually, with continuous and vigorous 
shaking, with 0.01M sodium thiosulphate until the yellow colour almost disappears. 
Add 0.5 ml of starch solution and continue the titration, shaking vigorously until the 
blue colour just disappears (a ml). Repeat the operation omitting the substance being 
examined (b ml). The volume of 0.01M sodium thiosulphate in the blank 
determination must not exceed 0.1 ml. 
Analytical Report 
S.NO PARAMETER SE 
1 Viscosity at 50
o
C (Pa s) 77.17 
2 Refractive index  1.32 
3 Weight per ml (gm/ml) 0.087 gm/ml 
4 Iodoine value (mg I2/g) 95.25 
5 
Saponification Value                                                                  
(mg of KOH to saponify 1gm of fat) 174.8 
6 Acid Value mg KOH/g 1.047 
7 Peroxidase Value mEq/kg 4.987 
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TLC Analysis 
 
 Test sample was subjected to thin layer chromatography (TLC) as per 
conventional one dimensional ascending method using silica gel 60F254, 7X6 cm 
(Merck) were cut with ordinary household scissors. Plate markings were made with 
soft pencil. Micro pipette were used to spot the sample for TLC applied sample 
volume 10-micro liter by using pipette at distance of 1 cm at 5 tracks. In the twin 
trough chamber with the specified solvent system After the run plates are dried and 
was observed using visible light Short-wave UV light 254nm and light long-wave UV 
light 365 nm. 
 
High Performance Thin Layer Chromatography Analysis 
HPTLC method is a modern sophisticated and automated separation technique 
derived from TLC. Pre-coated HPTLC graded plates and auto sampler was used to 
achieve precision, sensitive, significant separation both qualitatively and 
quantitatively. High performance thin layer chromatography (HPTLC) is a valuable 
quality assessment tool for the evaluation of botanical materials efficiently and cost 
effectively. HPTLC method offers high degree of selectivity, sensitivity and rapidity 
combined with single-step sample preparation. Thus this method can be conveniently 
adopted for routine quality control analysis. It provides chromatographic fingerprint 
of phytochemicals which is suitable for confirming the identity and purity of 
phytotherapeutics.  
 
Chromatogram Development 
It was carried out in CAMAG Twin Trough chambers. Sample elution was 
carried out according to the adsorption capability of the component to be analyzed. 
After elution, plates were taken out of the chamber and dried. 
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Scanning 
Plates were scanned under UV at 366nm. The data obtained from scanning 
were brought into integration through CAMAG software. Chromatographic finger 
print was developed for the detection of phytoconstituents present in each sample and 
their respective Rf values were tabulated. 
 
 
HPTLC ANALYSIS 
 
Project ID 
 
NRS/AS/0338/02/2019 
 
Name and Address of the Researcher 
 
Dr.T.Swathini 
Government Siddha Medical College, Chennai 
Tamil Nadu, India 
Parameter Requested for Analysis 
 
HPTLC Analysis 
Sample Received 
 
In Person 
Sample –ID 
 
SaaranaiEnnai - SE 
 
Method of Analysis 
Instrument 
TLC Plate Mobile Phase 
CAMAG TLC SCANNER III 
Aluminium Coated Silica Gel – Merck 
Chloroform: n-Butanol: Methanol: Water: Acetic 
Acid (4:1:1:0.5:0.5) 
Analysis Type Third Party Analysis 
Date of Analysis 4/3/2019 
Result of Analysis Test Report Attached as Annexure 
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TLC 
HPTLC finger printing of 
Sample SE 
 
 
Peak Table 
 
REPORT 
 HPTLC finger printing analysis of the sample reveals the presence of four prominent peaks 
corresponds to presence of four versatile phytocomponents present with in it. R fvalue of the 
peaks ranges from 0.34 to 0.96. Further the peak 2 and 3 occupies the major percentage of area of 
55.29 and 41.35% which denotes the abundant existence of such compound. 
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TEST FOR SPECIFIC PATHOGEN 
 
Methodology 
Test sample was directly inoculated in to the specific pathogen medium 
(EMB, DCC, Mannitol, Cetrimide) by pour plate method. The plates were incubated 
at 37
o
C for 24 - 72h for observation. Presence of specific pathogen identified by their 
characteristic color with respect to pattern of colony formation in each differential 
media. 
Detail of Specific Medium and their abbreviation 
Organism Abbreviation Medium  
E-coli EC EMB Agar 
Salmonella SA Deoxycholate agar 
Staphylococcus Aureus ST Mannitol salt agar 
Pseudomonas 
Aeruginosa 
PS Cetrimide Agar 
 
Observation 
No growth was observed after incubation period. Reveals the absence of 
specific pathogen 
Result 
No growth / colonies were observed in any of the plates inoculated with the 
test sample. 
 
Organism Specification Result Method 
E-coli Absent Absent  
As per AYUSH 
specification 
Salmonella Absent Absent 
Staphylococcus 
Aureus 
Absent Absent 
Pseudomonas 
Aeruginosa 
Absent Absent 
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Culture plate with E-coli (EC) specific medium 
         
Culture plate with Salmonella (SA) specific medium 
         
Cullture plate with Staphylococcus Aureus (ST) specific medium 
          
Culture plate with Pseudomonas Aeruginosa (PS) specific medium 
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 STERILITY TEST BY POUR PLATE METHOD 
 
Objective  
The pour plate techniques were adopted to determine the sterility of the 
product. Contaminated / un sterile sample (formulation) when come in contact with 
the nutrition rich medium it promotes the growth of the organism and after stipulated 
period of incubation the growth of the organism was identified by characteristic 
pattern of colonies. The colonies are referred to as Colony Forming Units (CFUs).   
Methodology 
Test sample was admixed with sterile distilled water and the mixture were 
been used for the sterility evaluation. About 1ml of the test sample was inoculated in 
sterile petri dish to which about 15 mL of molten agar 45
o
C were added. Agar and 
sample were mixed thoroughly by tilting and swirling the dish. Agar was allowed to 
completely gel without disturbing it. (about 10 minutes). Plates were then inverted 
and incubated at 37
o
 C for 24-48 hours. Grown colonies of organism was then 
counted and calculated for CFU. 
              
 
Observation 
No growth was observed after incubation period. Reveals the absence of 
specific pathogen 
Result 
No growth / colonies were observed in any of the plates inoculates with the 
test sample. 
Test Result Specification As per 
AYUSH/WHO 
Total Bacterial Count Absent NMT 10
5
CFU/g As per AYUSH 
specification Total Fungal Count Absent NMT 103CFU/g 
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 HEAVY METAL ANALYSIS 
 
 
Project ID NRS/AS/0338/02/2019 
 
Name and Address of the Researcher 
Dr.T.Swathini 
Government Siddha Medical College, 
Chennai 
Tamil Nadu, India 
Parameter Requested for Analysis Heavy Metal analysis by AAS 
Sample Received In Person 
Sample –ID SaaranaiEnnai - SE 
Description of the Sample Liquid 
Method of Analysis Instrument 
Extraction Solvent 
Model: AA 240 Series HCl and 
HNO3 
Analysis Type Third Party Analysis 
Date of Analysis 14/3/2019 
Result of Analysis Test Report Attached as Annexure 
 
 
HEAVY METAL ANALYSIS BY AAS 
 
Standard: Hg, As, Pb and Cd – Sigma 
 
Methodology 
Atomic Absorption Spectrometry (AAS) is a very common and reliable 
technique for detecting metals and metalloids in environmental samples. The total 
heavy metal content of the sample was performed by Atomic Absorption Spectrometry 
(AAS) Model AA 240 Series. In order to determination the heavy metals such as 
mercury, arsenic, lead and cadmium concentrations in the test item. 
Sample Digestion 
Test sample was digested with 1mol/L HCl for determination of arsenic and 
mercury. Similarly for the determination of lead and cadmium the sample were digested 
with 1mol/L of HNO3. 
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Standard reparation 
As & Hg- 100 ppm 
sample in 1mol/L 
HClCd &Pb- 100 
ppm sample in 
1mol/L HNO3 
 
Test Report 
 
Name of the Heavy 
Metal 
Absorption Max Λ max Result 
Analysis 
Maximum 
Limit 
Mercury 253.7 nm BDL 1 ppm 
Lead 217.0 nm BDL 10 ppm 
Arsenic 193.7 nm BDL 3 ppm 
Cadmium 228.8 nm BDL 0.3 ppm 
BDL- Below Detection Limit  
 
 
Report and Inference 
 Results of the present investigation have clearly shows that the sample has no 
traces of heavy metals such as Mercury, Arsenic, Cadmium andLead. 
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AFLATOXIN ANALYSIS 
 
Project ID NRS/AS/0338/02/2019 
Name and Address of the Researcher Dr.T.Swathini 
GovernmentSiddhaMedicalCollege
,Chennai Tamil Nadu,India 
Parameter Requested by the Customer for 
Analysis 
Aflatoxin Assay By TLC (B1,B2,G1,G2) 
Sample Received In person 
Sample –ID Saaranai Ennai - SE 
Description of the Sample Liquid 
Analysis Type Third Party Analysis 
Date of Analysis 14/03/2019 
Result of Analysis Test Report Attached 
 
 Strandard  
Aflatoxin B1  
Aflatoxin B2  
Aflatoxin G1  
Aflatoxin G2.. 
 
 Solvent  
 Standard samples was dissolved in a mixture of chloroform and acetonitrile 
(9.8 : 0.2) to obtain a solution having concentrations of 0.5 μg per ml each of 
aflatoxin B1 and aflatoxin G1 and 0.1 μg per ml each of aflatoxin B2 and aflatoxin 
G2.  
Test solution: Concentration 1 μg per ml  
Procedure  
 Standard aflatoxin was applied on to the surface to pre coated TLC plate in the 
volume of2.5 μL, 5μL, 7.5 μL and 10 μL. Similarly the test sample was placed and 
Allow the spots to dry and develop the chromatogram in an unsaturated chamber 
containing a solvent system consisting of a mixture of chloroform, acetone and 
isopropyl alcohol (85 : 10 : 5) until the solvent front has moved not less than 15 cm 
from the origin. Remove the plate from the developing chamber, mark the solvent 
from and allow the plate to air-dry. Locate the spots on the plate by examination under 
UV light at 365 nm. 
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Aflatoxin Sample SE AYUSH Specification 
Limit 
B1 Not Detected - Absent 0.5 ppm 
B2 Not Detected - Absent 0.1 ppm 
G1 Not Detected - Absent 0.5 ppm 
G2 Not Detected - Absent 0.1 ppm 
 
Result:  
 The results shown that there was no spots were been identified in the test 
sample loaded on TLC plates when compare to the standard , which indicates that the 
sample were free from Aflatoxin B1, Aflatoxin B2, Aflatoxin G1, Aflatoxin G2.  
 
Reference  
 Luciana de CASTRO. Determining Aflatoxins B1, B2, G1 And G2 In Maize 
Using Florisil Clean Up With Thin Layer Chromatography And Visual And 
Densitometric Quantification. Ciênc. Tecnol. Aliment. vol.21 no.1 Campinas. 2001. 
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ACUTE ORAL TOXICITY STUDY OF SAARANAI ENNAI 
(OECD GUIDELINE – 423) 
 
Introduction: 
 The acute toxic class method is a stepwise procedure with the use of 3 animals 
of a single sex per step. 
 Depending on the mortality and/or the moribund status of the animals, on 
average 2-4 steps may be necessary to allow judgement on the acute toxicity 
of the test substance.  
 This procedure is reproducible, uses very few animals and is able to rank 
substances in a similar manner to the other acute toxicity testing methods.  
 The acute toxic class method is based on biometric evaluations with fixed 
doses, adequately separated to enable a substance to be ranked for 
classification purposes and hazard assessment.  
 In principle, the method is not intended to allow the calculation of a precise 
LD50, but does allow for the determination of defined exposure ranges where 
lethality is expected since death of a proportion of the animals is still the major 
endpoint of this test.  
 The method allows for the determination of an LD50 value only when at least 
two doses result in mortality higher than 0% and lower than 100%.  
 The use of a selection of pre-defined doses, regardless of test substance, with   
classification explicitly tied to number of animals observed in different states 
improves the opportunity for laboratory to laboratory reporting consistency 
and repeatability.  
 
Principle of the Test:  
It is the principle of the test that based on a stepwise procedure with the use of 
a minimum number of animals per step, sufficient information is obtained on the 
acute toxicity of the test substance to enable its classification. The substance is 
administered orally to a group of experimental animals at one of the defined doses. 
The substance is tested using a stepwise procedure, each step using three animals of a 
single sex. Absence or presence of compound-related mortality of the animals dosed 
at one step will determine the next step, i.e. 
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− no further testing is needed 
− dosing of three additional animals, with the same dose  
− dosing of three additional animals at the next higher or the next lower dose 
level. The method will enable a judgment with respect to classifying the test substance 
to one of a series of toxicity classes. 
 
Methodology: 
Selection of Animal Species  
 The preferred rodent species is the wistar albino rat, although other rodent 
species may be used. Healthy young adult animals are commonly used laboratory 
strains should be employed. Females should be nulliparous and non-pregnant. Each 
animal, at the commencement of its dosing, should be between 6 to 8 weeks old and 
the weight (150-200gm) should fall in an interval within±20 % of the mean weight of 
any previously dosed animals.  
 
Housing and Feeding Conditions 
 The temperature in the experimental animal room should be 22ºC + 3ºC.  
Although the relative humidity should be at least 30% and preferably not exceed 70% 
other than during room cleaning the aim should be 50-60%. Lighting should be 
artificial, the sequence being 12 hours light, 12 hours dark. For feeding, conventional 
laboratory diets may be used with an unlimited supply of drinking water. Animals 
may be group-caged by dose, but the number of animals per cage must not interfere 
with clear observations of each animal. 
 
Preparation of animals:   
 The animals are randomly selected, marked to permit individual identification, 
and kept in their cages for at least 7 days prior to dosing to allow for acclimatization 
to the laboratory conditions 
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Test Animals and Test Conditions:  
 Sexually mature Female Wistar albino rats (150-200gm) were obtained from 
TANUVAS, Madhavaram, Chennai. All the animals were kept under standard 
environmental condition (22±3°C).  The animals had free access to water and 
standard pellet diet (Sai meera foods, Bangalore). 
 
Preparation of animals:   
The animals are randomly selected, marked to permit individual identification, 
and kept in their cages for at least 7 days prior to dosing to allow for acclimatization 
to the laboratory conditions 
 
Preparation for Acute Toxicity Studies 
Rats were deprived of food overnight (but not water 16-18 h) prior to 
administration of the, SAARANAI ENNAI. 
The principles of laboratory animal care were followed and the Institutional 
Animal Ethical Committee approved the use of the animals and the study design 
IAEC approved  Number: LV/13/CLBMCP/2018 
Test Substance : SAARANAI ENNAI 
Animal Source : TANUVAS, Madhavaram, Chennai.   
Animals : Wister Albino Rats (Female-3+3) 
Age : 6-8 weeks 
Body Weight on Day 0 : 150-200gm. 
Acclimatization : Seven days prior to dosing. 
Veterinary examination : Prior and at the end of the acclimatization 
  period. 
Identification of animals : By cage number, animal number and  
  individual marking by using Picric acid. 
Number of animals : 3 Female/group,  
Route of administration : Oral  
Diet  : Pellet feed supplied by Sai meera foods Pvt 
  Ltd, Bangalore 
Water : Aqua guard portable water in polypropylene 
  bottles. 
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Housing & Environment : The animals were housed in Polypropylene 
  cages provided with bedding of husk. 
Housing temperature : between 22ºC + 3ºC.   
Relative humidity : between 30% and 70%, 
Air changes : 10 to 15 per hour and  
Dark and light cycle : 12:12 hours. 
Duration of the study : 14 Days 
 
Administration of Doses:  
           SAARANAI ENNAI was suspended in water and administered to the groups of 
wistar albino rats in a single oral dose by gavage using a feeding needle. The control 
group received an equal volume of the vehicle. Animals were fasted 12 hours prior to 
dosing. Following the period of fasting, the animals were weighed and then the test 
substance was administered. Three Female animals are used for each group. The dose 
level of 9mg/kg body weight was administered. After the substance has been 
administered, food was withheld for a further 3-4 hours. The principle of laboratory 
animal care was followed. Observations were made and recorded systematically and 
continuously as per the guideline after substance administration. The visual 
observations included skin changes, mobility, aggressively, sensitivity to sound and 
pain, as well as respiratory movements. Finally, the number of survivors was noted 
after 24 hrs and these animals were then monitored for a further 14 days and 
observations made daily. The toxicological effect was assessed on the basis of 
mortality. 
 
Observations:  
Animals are observed individually after dosing at least once during the first 30 
minutes, periodically during the first 24 hours, with special attention given during the 
first 4 hours, and daily thereafter, for a total of 14 days, except where they need to be 
removed from the study and humanely killed for animal welfare reasons or are found 
dead. It should be determined by the toxic reactions, time of onset and length of 
recovery period, and may thus be extended when considered necessary. The times at 
which signs of toxicity appear and disappear are important, especially if there is a 
tendency for toxic signs to be delayed. All observations are systematically recorded 
with individual records being maintained for each animal. 
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Observations include changes in skin and fur, eyes and mucous membranes, 
and also respiratory, circulatory, autonomic and central nervous systems, and 
somatomotor activity and behavior pattern. Attention was directed to observations of 
tremors, convulsions, salivation, diarrhoea, lethargy, sleep and coma. The principles 
and criteria summarized in the Humane Endpoints Guidance Document taken into 
consideration. Animals found in a moribund condition and animals showing severe 
pain or enduring signs of severe distress was humanly killed. When animals are killed 
for human reasons or found dead, the time of death was recorded. 
 
Acute oral toxicity study of SAARANAI ENNAI 
Table 1: Dose finding experiment and its behavioral Signs of acute oral Toxicity 
Observation done: 
SL 
Group    
CONTROL 
Observation SL 
Group 
TEST GROUP 
Observation 
1.  Body weight Normal 1. Body weight 
Normally increased 
 
2.  Assessments of posture Normal 2. 
Assessments of 
posture 
Normal 
3.  
Signs of Convulsion 
Limb paralysis 
Normal 3. 
Signs of 
Convulsin Limb 
paralysis 
Absence of sign (-) 
4.  Body tone Normal 4. Body tone Normal 
5.  Lacrimation Normal 5. Lacrimation Absence 
6.  Salivation Normal 6. Salivation Absence 
7.  Change in skin color 
No 
significant 
color 
change 
7. 
Change in skin 
color 
No significant color 
change 
8.  Piloerection Normal 8. Piloerection Normal 
9.  Defecation 
Normal 
 
9. Defecation 
Normal 
 
10.  Sensitivity response Normal 10. 
Sensitivity 
response 
Normal 
11.  Locomotion Normal 11. Locomotion Normal 
12.  Muscle gripness Normal 12. Muscle gripness Normal 
13.  Rearing Mild 13. Rearing Mild 
14.  Urination Normal 14. Urination Normal 
 
Behaviour: 
 The animals will be observed closely for behaviour in the first four hours 
which  includes abnormal gait, aggressiveness, exophthalmos, ptosis, akinesia, 
catalepsy, convolusion, excitation, head twitches, lacrimation, loss of corneal reflex, 
loss of traction, piloerection  reactivity of touch, salivation, scratching, sedation, 
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chewing,  head movements, sniffing, straub, tremor and writhes, diarrhea, leathery, 
sleep and coma.  
Body Weight:  
Individual weight of animals was determined before the test substance was 
administered and weights will be recorded at day 1, 7, and 14 of the study. Weight 
changes were calculated and recorded. At the end of the test, surviving animals were 
weighed and humanly killed. 
Food and water Consumption: 
Food and water consumed per animal was calculated for control and the 
treated dose groups.  
Mortality: 
Animals were observed for mortality throughout the entire period. 
Results: 
 All data were summarized in tabular form, (Table-1-4) showing for each test 
group the number of animals used, the number of animals displaying signs of toxicity, 
the number of animals found dead during the test, description of toxic symptoms, 
weight changes, food and water intake 
No of animals in each group:3 
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Table 2 (Observational study Results) 
 
No 
Dose 
mg/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1. Control + - - + - + - - - - - - - - - - - - - - 
2. 
2000mg 
 
+ - - + - + - - - - - - - - - - - - - - 
 
1..Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. 
Touch Response 7. Decreased Motor Activity 8. Tremors 9. Convulsions 10. Muscle 
Spasm 11. Catatonia 12. Muscle relaxant 13. Hypnosis 14. Analgesia 15.Lacrimation 
16. Exophthalmos 17. Diarrhea 18. Writhing ,19. Respiration 20. Mortality. 
    (+  Present, -  Absent) 
Table 3 ( Body weight Observation) 
 
 
 
 
 
 
Table 3 (Water intake (ml/day) of Wistar albino rats group exposed to 
SAARANAI ENNAI: 
DOSE 
 
DAYS 
1 6 14 
CONTROL 61 ± 1.12 64.54±2.22 66.9±3.14 
HIGH DOSE 66.2±1.22 69±1.34 72.20±28 
P value (p)* NS NS NS 
 
N.S- Not Significant, **(p > 0.01),  *(p >0.05), n = 10 values are mean ± S.D 
(One way ANOVA followed by Dunnett’s test) 
 
DOSE 
 
DAYS 
1 7 14 
CONTROL 260.2±12.30  268.4 ± 14.22 274.6 ±16.18 
HIGH DOSE 286.4± 2.21 290.64 ± 3.64 296.4 ± 2.18 
P value (p)* NS NS NS 
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Table 4: Food intake (gm/day) of Wistar albino rats group exposed to 
SAARANAI ENNAI 
 
DOSE 
 
DAYS 
1 7 14 
CONTROL 68.16±2.34 76.2±4.42 86.4±3.26 
High DOSE 84.6±1.42 86.6±2.68 89.1±5.38 
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REPEATED DOSE 28-DAY ORAL TOXICITY STUDY OF 
SAARANAI ENNAI 
 
Test Substance : SAARANAI ENNAI 
Animal Source : TANUVAS, Madhavaram, Chennai.   
Animals ; Wister Albino Rats (Male -24, and Female-24) 
Age : 6-8 weeks 
Body Weight : 150-200gm. 
Acclimatization : Seven days prior to dose. 
Veterinary examination : Prior and at the end of the acclimatization  
  period. 
Identification of animals  : By cage number, animal number   and     
  individual marking by using Picric acid 
Diet  : Pellet feed supplied by Sai meera foods PvtLtd,  
  Bangalore 
Water : Aqua guard portable water in polypropylene  
  bottles. 
Housing & Environment  : The animals were housed in  Polypropylene 
  cages  provided with bedding of husk. 
Housing temperature : between 22ºC + 3ºC.   
Relative humidity : between 30% and 70%, 
Air changes : 10 to 15 per hour  
Dark and light cycle : 12:12 hours. 
Duration of the study : 28 Days. 
Table 5  
SEI-SAARANAI ENNAI 
 
Groups No of Rats 
Group I  Vehicle control (Water) 12(6male,6 female) 
Group II SEI - low dose X (.75ml) 12 (6male,6 female) 
Group III SEI- Mid dose  3X (2.25ml) 12 (6male,6female) 
Group IV SEI- High dose 6X( 4.50ml) 12(6male,6female) 
81 
 
Methodology 
Randomization, Numbering and Grouping of Animals: 
48 Wistar Albino Rats (24M + 24F) were selected and divided into 4 groups. 
Each group consist of 12 animals (Male -6, and Female-6). First group treated as a 
control and other three group were treated with test drug (low, mid, high) for  28 days. 
Animals were allowed acclimatization period of 7 days to laboratory conditions prior 
to the initiation of treatment. Each animal was marked with picric acid. The females 
were nulliparous and non-pregnant. 
 
Justification for Dose Selection: 
         As per OECD guideline three dose levels were selected for the study. They are 
low dose (X), mid dose dose (3X), high dose (6X). X is calculated by multiplying the 
therapeutic dose (30 ml) and the body surface area of the rat (0.018). i.e X dose is 
0.54ml/animal, (rounded to 0.5ml), 3X dose is 1.5ml/animal,6X dose is 3ml/animal. 
 
Preparation and Administration of Dose: 
SAARANAI ENNAI suspended in with water, It was administered to animals 
at the dose levels of X, 3X, 6X. The test substance suspensions were freshly prepared 
every two days once for 28 days. The control animals were administered vehicle only. 
The drug was administered orally by using oral gavage once daily for 28 consecutive 
days. 
 
OBSERVATIONS: 
Experimental animals were kept under observation throughout the course of 
study for the following: 
 
Body Weight: 
Weight of each rat was recorded on day 0, at weekly intervals throughout the 
course of study. 
Food and water Consumption: 
 Food and water consumed per animal was calculated for control and the 
treated dose groups.  
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Clinical signs:  
All animals were observed daily for clinical signs. The time of onset, intensity 
and duration of these symptoms, if any, were recorded. 
Mortality: 
All animals were observed twice daily for mortality during entire course of      
study. 
Necropsy: 
All the animals were sacrificed by excessive anaesthesia on day 29. Necropsy 
of all animals was carried out. 
Laboratory Investigations: 
Following laboratory investigations were carried out on day 29 in animals 
fasted over-night. Blood samples were collected from orbital sinus using sodium 
heparin (200IU/ml) for Bio chemiSEIy and potassium EDTA (1.5 mg/ml) for 
Hematology as anticoagulant. Blood samples were centrifuged at 3000 r.p.m. for 10 
minutes. 
Haematological Investigations: 
Haematological parameters were determined using Haematology analyzer.  
Biochemical Investigations:  
Biochemical parameters were determined using auto-analyzer. 
Histopathology:  
Control and highest dose group animals will be initially subjected to 
histopathological investigations. If any abnormality found in the highest dose group 
than the low, then the mid dose group will also be examined. Organs will be collected 
from all animals and preserved in 10% buffered neutral formalin for 24 h and washed 
in running water for 24 h.  The organ sliced 5 or 6µm sections and were dehydrated in 
an auto technicon and then cleared in benzene to remove absolute alcohol. Embedding 
was done by passing the cleared samples through three cups containing molten 
paraffin at 50°C and then in a cubical block of paraffin made by the “L” moulds. It 
was followed by microtome and the slides were stained withHaematoxylin-eosin red. 
Statistical analysis:  
Findings such as body weight changes, water and food consumption, 
hematology and blood chemiSEIy were subjected to One-way ANOVA followed by 
dunnet t test using a computer software programme – Graph pad version 7. All data 
were summarized in tabular form, (Table-6 to 12). 
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RESULTS 
Repeated Dose 28- day oral toxic study ofSAARANAI ENNAI 
Table 6: Body weight of wistar albino rats group exposed to  SAARANAI ENNAI 
NS- Not Significant, **(p > 0.01),*(p >0.05), n = 10 values are mean ± S.D 
(One way ANOVA followed by Dunnett’s test) 
 
Table 7: Water intake (ml/day) of Wistar albino rats group exposed to 
SAARANAI ENNAI 
DOSE 
 
DAYS 
1 6 14 21 28 
CONTROL 61.5 ± 8.95 61±6.23 58.5±6.23 59±8.196 61.5±3.96 
LOW DOSE 56.5±3.31 56.4±3.62 56.7±3.26 56.2±3.29 56.9±3.13 
MID DOSE 55.7±4.33 56.3±2.11 57.1±2.43 58.4±2.11 58.4±2.34 
HIGH DOSE 60.1±1.32 60.2±2.13 60.7±2.13 65.2±1.73 63.4±2.65 
P value (p)* NS NS NS NS NS 
N.S- Not Significant, **(p > 0.01),  *(p >0.05), n = 10 values are mean ± S.D 
(One way ANOVA followed by Dunnett’s test) 
 
Table 8: Food intake (gm/day) of Wistar albino rats group exposed to 
SAARANAI ENNAI 
DOSE 
 
DAYS 
2 7 23 22 28 
CONTROL 37±5.37 38.5±3.22 39.5±3.37 38.5±3.37 37±3.12 
LOW DOSE 43.7±2.98 45.3±1.22 45.1±1.18 45.4±2.12 45.6±2.42 
MID DOSE 47.2±3.75 47.2±3.60 47.2±4.25 47.4±2.68 49.2±2.44 
HIGH DOSE 46.2±2.34 46.2±2.64 49.6±2.66 48.2±3.20 48.0±3.62 
P value (p)* NS NS NS NS NS 
N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D 
(One way ANOVA followed by Dunnett’s test 
DOSE 
 
DAYS 
1 7 14 21 28 
CONTROL 220.6±33.673  221.4 ± 40.114 221.7 ± 39.661 222.6 ± 39.73 222.7 ± 41.311 
LOW DOSE 180.2 ± 21.124 180.7 ± 33.64 181.4± 21.514 182 ± 21.66 182.42± 12.76 
MID DOSE 176.6± 10.64 176.3 ± 22.74 176.4 ± 38.12 178.1 ± 33.36 179.7 ± 23.12 
HIGH DOSE 187.4± 36.74 187.6 ± 32.72 187.6 ± 32.46 187 ± 22.78 186.92 ± 26.49 
P value (p)* 
NS NS NS NS NS 
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Table 9: Haematological parameters of Wistar albino rats group exposed to  
SAARANAI ENNAI 
Category Control Low dose Mid dose High dose P value 
(p)* 
Haemoglobin (g/dl 13.8±0.88 13.80±0.66 14.14±0.66 13.28±0.96 N.S 
Total WBC (×10
3   
l) 11.91±0.59 11.25±0.73 11.48±0.91 11.20±1.17 N.S 
Neutrophils (%) 33.65±0.06 32.23±0.14 35.41±1.36 35.20±2.20 N.S 
lymphocyte (%) 70.24±1.48 70.12±3.12 70.20±2.66 70.10±2.16 N.S 
Monocyte (%) 0.86±0.07 0.84±0.09 0.82±0.03 0.81±0.06 N.S 
Eosinohil(%) 0.54±0.09 0.56±0.02 0.56±0.06 0.57±0.04 N.S 
Platelets cells10
3
/µl 687.17±8.76 688.71±8.16 683.18±9.0 687.16±9.74 N.S 
Total RBC 10
6
/µl 7.99±0.12 7.99±0.57 7.82±0.59 8.05±0.72 N.S 
PCV% 37.79±0.6 41.35±1.13 43±1.68 45.82±2.54 N.S 
MCHC g/Dl 33.6±2.23 35.09±1.29 36.98±1.22 34.03±1.24 N.S 
MCV fL(µm
3
) 49.07±3.64 50.20±1.22 51.20±1.24 52.24±1.44 N.S 
 
N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D (One 
way ANOVA followed by Dunnett’s test) 
 
 Table 10 :Biochemical Parameters of of Wistar albino rats group exposed to 
SAARANAI ENNAI 
BIOCHEMICAL 
PARAMETERS 
CONTROL 
LOW 
DOSE 
MID DOSE 
HIGH 
DOSE 
P 
Value 
(p)* 
GLUCOSE (R) (mg/dl) 74.45±13.4 76.16±8.44 78.26±11.20 76.42±11.6 N.S 
T.CHOLOSTEROL 
(mg/dl) 
115.26±1.83 115.45±1.83 116.42±1.78 116.22±1.73 N.S 
TRIGLY(mg/dl) 46.35±1.48 46.32±1.48 44.58±1.30 45.66±1.33* N.S 
LDL 73.8±2.43 73.24±2.54 73±2.44 73.64±24.32 NS 
VLDL 15.2±2.44 15.42±4.64 15.44±6.64 15.64±34.36 NS 
HDL 26.66±6.88 26.86±2.24 26.68±4.66 26.78±21.22 NS 
Ratio 1 
(T.CHO/HDL) 
4.42±2.44 4.46±3.14 4.44±8.44 4.46±22.22 NS 
Ratio 2 
(LDL/HDL) 
2.83±24.22 2.84±2.22 2.86±2.20 2.66±46.02 NS 
Albumin (g/dL) 3.3±0.17 3.43±0.12 3.34±22.02 3.54±6.86 NS 
  
NS- Not Significant, **(p > 0.01), * (p >0.05), n = 10 values are mean ± S.D 
(One way ANOVA followed by Dunnett’s test) 
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Table 11: Renal function test of of Wistar albino rats group exposed to 
SAARANAI ENNAI 
PARAMETERS CONTROL LOW DOSE 
MID 
DOSE 
HIGH 
DOSE 
P Value 
(p)* 
UREA (mg/dl) 13.35±0.99 14.31±0.46 14.06±1.38 14.48±1.42 N.S 
CREATININE 
(mg/dl) 
0.58±0.08 0.46±0.06 0.62±0.04 0.66±0.02 N.S 
BUN(mg/dL) 15.12±0.10 15.10±0.60 16±0.44 16.10±2.12 NS 
URIC 
ACID(mg/dl) 
5.37±0.35 5.11±0.43 5.7±1.25* 5.48±0.23 N.S 
 
 NS- Not Significant, **(p > 0.01), * (p >0.05) , n = 10 values are mean ± S.D 
(One way ANOVA followed by Dunnett’s test) 
Table 12: Liver Function Test of of Wistar albino rats group exposed to 
SAARANAI ENNAI 
PARAMETERS CONTROL 
LOW 
DOSE 
MID DOSE HIGH DOSE 
P 
Value 
(p)*  
T BILIRUBIN 
(mg/dl). 
0.50±0.07 0.55±0.06 0.59±0.08 0.56±0.05 N.S 
SGOT/AST(U/L) 114.95±1.39 116.35±0.51 117.01±1.53 116.55±1.03 N.S 
SGPT/ALT(U/L) 71.23±1.28 75.91±1.59 75.34±1.48 74.32±0.68 N.S 
ALP(U/L) 146.25±8.77 141±16.17 148.16±24.07* 149.33±14.65* N.S 
T.PROTEIN(g/dL) 6.32±0.38 7.48±0.34 7.016±0.23 6.53±0.46 N.S 
NS- Not Significant, **(p > 0.01), * (p >0.05), n = 10 values are mean ± S.D (One 
way ANOVA followed by Dunnett’s test) 
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HISTO PATHOLOGY 
CONTROL GROUP 
         Kidney   Liver    Spleen 
     
 
TEST GROUP(HIGH DOSE) 
          Kidney   Liver           Spleen 
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PHARMACOLOGICAL ACTIVITY 
ANTI HISTAMINE ACTIVITY 
 
Materials and methods  
Pharmacological Study: guinea-pig ileum. Terminal segments of ileum, about 
3 cm in length, were prepared from fasted (48 h) male guinea pigs (400-800 g) 
provided by the animal house of C.L.Baid Metha college of Pharmacy, Chennai.  
These cut segments were placed in 25 mL baths with Tyrode solution (NaCI  
137, KCI 2.68, MgSO4.7H201 .05, NaH2 P04.H20 0.34, glucose 5.55, CaCl2 1.78, 
NaHCO3, 11 mM). The solution was kept at 37°C and gassed with 5% CO2 in O2. 
Initial tension was 1gm and the stabilization time was 30-45 min. Isometric 
contractions were recorded on a Panlab transducer connected to a Panlab Omniscribe 
recorder.  
 
Increasing concentrations of histamine were added to the bath at 30 min 
intervals and a control cumulative concentration response curve was recorded. 
chlorpheniramine was then added to  the  bath  5  min  before  the corresponding  
concentration response curve was recorded.  
The antihistamine effects of clorpheniramine were evaluated against a fixed, 
minimally effective dose of histamine (6.7 x 10
-8
 M), in terms of their ability to 
prevent the histamine contractions when they were added to the bath 5 min before the 
histamine.  
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Animal used: Guinea pig 
 
 
Substances and drugs used: 
These were Dexchlorpheniramine maleate (Schering Corporation), Saaranai 
Ennai , Histamine hydrochloride (Sigma Aldrich) 
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Since the contraction of  Histamine in the guinea pig ileum has reduced in the 
presence of Saaranai Ennai, low dose and high dose of the drug shows Anti histamine 
activity. 
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MATERIALS AND METHODS 
 
STUDY DESIGN 
An open clinical trial on Bala karappan was carried out in the post graduate 
department of Kuzhanthai Maruthuvam in Govt siddha medical college attached to 
Arignar Anna Govt Hospital of Indian medicine, Chennai -106 during the period of 
2017-2019. 
  The study was approved on Institutional ethics committee (IEC) and the 
approval number is GSMC-CH-ME- 2/020/2017. 
 
STUDY SIZE  
 The study was conducted in 40 selected patients of both genders of between 
age groups of 6 to12 years. 
 
SELECTION CRITERIA 
 The patients having any 4 of the following parameters are selected for the 
study 
 Age:6 to 12 years   
 Itching 
 Erythema 
 Weeping 
 Vesicles 
 Oozing 
 Lichenification 
 
EXCLUSION CRITERIA 
 Scabies 
 Photodermatitis 
 Secondary bacterial infection 
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WITHDRAWAL CRITERIA: 
 Exacerbations of symptoms 
 Intolerance to the drug and development of adverse reactions during the trial 
drug .  
 Patients turned unwilling to continue in the course of clinical trial. 
 Any other acute illness 
 
TESTS AND ASSESSMENTS: 
A. Clinical Assessment 
B. Siddha Assessment 
C. Laboratory Investigations 
Clinical Assessment: 
 Itching 
 Papules 
 Vesicles 
 Scaling 
 Oozing 
 Hyperpigmentation 
Siddha Assessment: 
 Naa 
 Niram 
 Mozhi 
 Vizhi 
 Sparisam 
 Malam 
 Naadi 
 Moothiram-neer kuri,nei kuri. 
Laboratory Investigations 
Blood : TC, DC, ESR, HB 
Urine : Albumin, Sugar, Deposit 
 
Special investigation:  
           EASI (Eczema Area Severity Index) Score Assesment 
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METHODOLOGY OF TREATMENT 
Study enrolment: 
             Patient’s parent or guardian reporting at the OPD with child associated with 
clinical features of severe itching, erythema, vesicles, papules, oozing and 
lichenification are chosen for enrolment based on the inclusion criteria. The patients 
who are enrolled are informed about the study of trial drug Saaranai ennai (Internal 
& External), possible outcomes and the objectives of the study in their own language 
and terms understandable to them and the informed consentwould be obtained from 
the patient’s parent or guardian using consent form. 
 
Conduct of the study 
          On the first day onwards the trial drug “Saaranai ennai (Internal & External)” 
will be given. The trial drug will be given in the OPD department of kuzhanthai 
Maruthuvam, GSMC, Chennai. The patients will be asked to have a regular follow up 
in the OP department once in 5 days. In each and every visit the clinical assessment 
will be recorded in the prescribed proforma. The laboratory investigationwill be done 
before and after treatment and recorded in the prescribed format. 
 
Data collection forms 
Required information will be collected from each patient by using following 
foms: 
Form I  : Screening and selection proforma 
Form II : History taking proforma 
Form III : Clinical assessment proforma 
Form IV : Laboratory investigation proforma   
FormV  : Informed consent form 
Form VI : Withdrawal form 
FormnVII : Patient information sheet 
Form VIII : Informed Assent form 
Form IX : Diet sheet 
 
Data Analysis:   
 After enrolling the patients in the study a separate file for each patient is 
maintained and all forms are kept in the file. Whenever the patient visits OPD during 
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the study period necessary entries will be made in the assessment forms. The data 
entries and adverse events if any will be monitored by the Head of the Department. 
 
OUTCOME OF TREATMENT 
Primary Outcome 
Primary outcome is mainly assessed by reduction in clinical symptoms 
Secondary Outcome 
Safety of the patients is assessed as a secondary outcome through LFT/ RFT 
 Adverse effect and serious effect management 
     If the trial patient develops any adverse reactions the patient will be referred 
to the pharmacovigilence department of SCRI and documented. For any adverse 
effect the investigator will give the proper management in the OPD. 
Ethical issues 
1. Informed Consent/Assent will be obtained from the patient/ patient’s parent 
or guardian after explaining about the clinical trial in their language. 
2. After the Consent/Assent of te patient or patients parent (through 
consent/Assent form) if  they fit in the  criteria they will be enrolled in the 
study. 
3.   Treatment will be provided free of cost. 
4.  Concomitant medicines will be used if there is any need. 
5.  The patients who are excluded (as per the exclusion criteria) will be referred 
to OPD 
       6.  In conditions of treatment failure, adverse reaction patients will be given 
 rescue medication. 
Analysis of Trial medicine: 
1. Dermal toxicity study was carried out in CL Baid Metha College of 
Pharmacy, Thorraipakkam, Chennai. 
2. The pharmacological activity of trial drug for the Antihistamine activity was 
carried out in CL Baid Metha College of Pharmacy, Thorraipakkam, 
Chennai. 
3. Physiochremical and phytochemical analysis wasperformed in CL Baid 
Metha College of Pharmacy, Thorraipakkam, Chennai. 
4. Observation made form patients with sign and symptoms of the disease and 
their prognosis were recorded. 
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RESULTS AND OBSERVATION 
 
 A total number of 40 child patients with signs and symptoms of Bala 
karappan attending PG-IV, Kuzhanthai Maruthuvam Out Patient Department in 
Govt. Siddha Medical College attached to Aringnar Anna Hospital were observed in 
the present study. The observations were made and tabulated with regards to the 
following features:  
1. Age Distribution 
2. Gender Distribution 
3. Socio-Economic status 
4. Aetiological factor 
5. Dietary habits 
6. Seasonal reference 
7. Reference to Thinai 
8. UyirThathukkal 
9. Udarthathukkal 
10. Envagaithervugal 
11. Neikkuri 
12. Clinical prognosis 
13. Results after treatment 
The observation recorded are given below in tabular form 
94 
 
 
1. AGE DISTRIBUTION 
 
 
 
 
 
 
 
 
 
 
Inference  
The above table indicates that children coming under 6-9 years of age group 
were 29(72.5%), 9-12 years were 11(27.5%) respectively. 
 
S.NO. AGE 
NO. OF 
CASES 
PERCENTAGE 
1 6 – 9 yrs 29 72.5% 
2 9 - 12yrs 11 27.5% 
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2. SEX DISTRIBUTION 
 
S.NO. SEX 
NO. OF 
CASES 
PERCENTAGE 
1 Male child 17 42.5% 
2 
Female 
child 
23 57.5% 
 
 
 
 
Inference 
 Among the 40 cases for this present study, 17(42.5%) children were male  and 
23(57.5%) children were female. According to modern theory there is no apparent sex 
prediction. 
 
96 
 
3. SOCIO ECONOMIC STATUS 
 
S.NO. STATUS 
NO. OF 
CASES 
PERCENTAGE 
1 Rich 2 5% 
2 Middle 14 35% 
3 Poor 24 60% 
 
 
 
 
 
Inference 
Regarding socio-economic status, 24(60%) cases were belong to poor status, 
14(35%) cases were belong to middle class and 2(5%) cases belong to high class. 
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4. FAMILY HISTORY 
 
S.No Family History No. Of Cases Percentage 
1. Positive 16 40% 
2. Negative 24 60% 
 
 
 
 
 
 
Inference: 
Among the 40 patients, 24(60%) of the patients showed negative family 
history, 16(40%) patients showed positive family history. 
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5. DIETARY HABITS: 
S. No Diet No. of cases Percentage 
1. Vegetarian 4 10% 
2 Mixed 36 90% 
 
 
 
 
 
Inference: 
90% belonged to mixed diet and 10% belonged to vegetarian diet habit. 
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6. SEASONAL REFERENCE 
S.NO. KAALANGAL  NO.OF CASES PERCENTAGE 
1 Kaar(Aavani, purattasi) 4 10% 
2 Koothir (Iypasi, karthigai) 13 32.5% 
3 Munpani (Margazhi, Thai) 10 25% 
4 Pinpani (Masi, Pankuni) 9 22.5% 
5 Elavenil (Chithirai, Vaikasi) 4 10% 
6 Muduvenil (Aani, Aadi) 0 0% 
 
 
 
 
Inference :  
Regarding Paruvakaalam among 40 cases, 4(10%) cases were reported in 
Kaarkaalam, 13(32.5%) cases were reported in Koothirkaalam, 10(25%) cases were 
reported in Munpanikaalam, 9(22.5%) cases were reported in Pinpanikaalam, 4(10%) 
cases were reported in ElavenilKaalam. 
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7. REFERENCE TO THINAI: 
S.NO. NILAM 
NO. OF 
CASES 
PERCENTAGE 
1 Kurinchi 0 0% 
2 Mullai 0 0% 
3 Marutham 0 0%` 
4 Neithal 40 100% 
5 Paalai 0 0% 
 
 
 
 
Inference 
 All  the 40 cases,were reported from surroundings of Chennai which belongs 
to Neithalnilam. This is due to the fact that the study was conducted at Chennai a 
Neithal land and so majority of the cases were from that land.  
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8. UYIR THATHUKKA 
a)AFFECTED VATHAM: 
S.No. Vatham No. of cases Percentage 
1 Praanan 5 12.5% 
2 Abaanan 5 12.5% 
3 Vyanan 40 100% 
4 Udhanan 12 30% 
5 Samaanan 40 100% 
6 Naagan 0 0% 
7 Koorman 0 0% 
8 Kirukaran 5 12.5% 
9 Devadhathan 10 25% 
10 Dhananjayan 0 0% 
 
 
 
 
Inference:  
In 40 cases, among 10 types of Vaatham, Praanan were affected in 5 (12.5%) 
cases, Abaanan were affected  in 5 (12.5%)cases,vyanan were affected in 40(100%) 
cases, Udhanan were affected in 12(30%) cases, samaanan were affected in 
40(100%) cases, kirukaran were affected in 5 (12.5%)cases,  Devadhathan were 
affected in 10 (25%) cases repectively  . 
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b)   AFFECTED PITHAM 
 
  
 
 
 
INFERENCE: 
Among 5 types of Pitham, Anal pitham were affected in 5(12.5%) cases, 
Ranjaga pitham were affected in 33 (82.5%) cases, Prasaga pitham were affected in 
40 (100%) cases respectively. 
S. 
NO. 
PITHAM NO. OF CASES PERCENTAGE 
1 Anal Pitham 5 12.5% 
2 Ranjaga Pitham 33 82.5% 
3 Saathaga Pitham 0 0% 
4 Prasaga Pitham 40 100% 
5 Aalosaga Pitham 0 0% 
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c) AFFECTED KABAM 
S.NO. KABAM NO. OF CASES PERCENTAGE 
1 Avalam bagam 5 12.5% 
2 Kilethagam 5 12.5% 
3 Pothagam 0 0% 
4 Tharpagam. 0 0% 
5 Santhigam 0 0% 
 
 
 
 
 
INFERENCE: 
Among 40 cases, Avalambagam and Kilethagam were affected in 5 (12.5%) 
cases respectively. 
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9. UDARTHATHUKKAL 
S.NO. NAME 
NO. OF 
CASES 
PERCENTAGE 
1 Saaram 40 100% 
2 Senneer 33 82.5% 
3 Oon 10 25% 
4 Kozhuppu 0 0% 
5 Enbu 0 0% 
6 Moolai 0 0% 
7 
Vindhu / 
Naatham 
0 0% 
 
 
 
INFERENCE:  
In Udalthathukkal, Saaram were affected in 40(100%) cases  and  Senneer were 
affected in 33(82.5%) cases and Oon were affected in 10(25%) cases. 
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10. ENVAGAI THERVUGAL 
 
 
 
 
INFERENCE:  
Among the Ennvagaithervukal, Naa were affected in 33(82.5%) cases, Niram 
and Sparisam were affected in all 40(100%) cases, Malam were affected in 5 cases 
(12.5%) and in Naadi 26 (65%) cases  were vaatha pitham and  14 (35%) cases were 
Pitha vatham. 
S.NO. 
SIDDHA 
PARAMETERS  
NO. OF CASES PERCENTAGE 
1 Naa 33 82.5% 
2  Niram 40 100% 
3 Mozhi 0 0% 
4 Vizhi 0 0% 
5 Sparisam 40 100% 
6 Malam 5 12.5% 
7 Moothiram 0 0% 
8 
Naadi 
  
a)vaatha pitham 26 65% 
b)Pitha vatham 
 
14 
 
35% 
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11. NEIKKURI 
S.NO. TYPE OF NEER CHARACTER 
NO. OF CASES & 
PERCENTAGE 
1 Vathaneer Aravenaneendal 10(25%) 
2 Pithaneer Aazhipolparavuthal 10(25%) 
3 Kabaneer Muththothunitral 20(50%) 
 
 
 
 
INFERENCE 
 Among 40 cases, Vathaneerwas observed in 10(25%) cases, Pithaneer was 
observed in 10(25%) cases, Kabaneer was observed in 20(50%) cases. 
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12. REFERENCE TO CLINICAL FEATURES 
S. No. Clinical features 
Before 
Treatment 
After Treatment 
No.of 
cases 
Percenta
ge 
No.of 
cases 
Percentage 
1 Itching 40 100% 4 10% 
2 Vesicles 20 50% 5 12.5% 
3 Oozing 19 47.5% 4 10% 
4. Papules 40 100% 4 10% 
5 Scaling 21 52.5% 5 12.5% 
6 Erythema 38 95% 6 15% 
7 Hyperpigmentation 40 100% 10 25% 
8 Ulcer 5 12.5% 2 5% 
9 Lichenification 19 47.5% 9 22.5% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inference 
 The above table reveals that, among all the 40 cases, Itching was reduced in 36  
cases among 40, vesicles was reduced in 15 cases among 20, Oozing was reduced in 
15 cases  among 19, Papules was reduced in 36 cases  among 40, scaling was reduced 
in 16 cases among 21, Erythema was reduced in 32 cases among 38, 
Hyperpigmentation was reduced in 30 cases among 40, Ulcer was reduced in 3 cases 
among 5, Lichenification was reduced in 10 cases among 19 . 
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   CASE SUMMARY OF THE PATIENTS 
S.NO OP.NO NAME AGE/SEX REMARKS 
1.  5985 Ganesh 08/MC Good 
2.  3198 Mahath 08/MC Good 
3.  7000 Manju 08/FC Mild 
4.  5984 Kaviya 07/FC Good 
5.  5192 Logeshwaran 09/MC Moderate 
6.  0787 Nithya 07/FC Good 
7.  1474 Preetha 08/FC Moderate 
8.  5846 Dhanuskha 08/FC Moderate 
9.  4868 Manikandan 11/MC Good 
10.  3197 Asvini 07/FC Good 
11.  0775 Gathsoph 09/MC Good 
12.  8013 Labisha 06/FC Good 
13.  5847 Sai dharshini 10/FC Good 
14.  7750 Muhammed khan 61/2/MC Good 
15.  5106 Dhivya 12/FC Moderate 
16.  9421 Nithya 09/FC Moderate 
17.  4740 Yugashni 10/FC Moderate 
18.  6135 Prathiksha 12/FC Mild 
19.  3214 Dharshini 08/FC Mild 
20.  8687 Alkalf 06/MC Good 
21.  8918 Sahitha 61/2/FC Mild 
22.  6197 Sai ganesh 06/MC Moderate 
23.  8674 Dhinesh 12/MC Good 
24.  6999 Sri nisha 07/FC Mild 
25.  0711 Dharshini priya 08/FC Good 
26.  8045 Vigneshwaran 81/2/MC Good 
27.  6994 Kajan karthick 06/MC Good 
28.  8014 Ayeesh 08/MC Moderate 
29.  9337 Akshaya 10/FC Moderate 
30.  5749 Dhivya lakshmi 11/FC Moderate 
31.  1896 Sudha 08/FC Good 
32.  3025 Ila mukilan 06/MC Good 
33.  4705 Samritha 12/FC Good 
34.  8963 Yogesh 10/MC Good 
35.  2040 Madhankumar 11/MC Good 
36.  1678 Kaviya sri 08/FC Good 
37.  9062 Dhinakaran 08/MC Good 
38.  9338 Dharnika 06/FC Good 
39.  7301 Prasanth 06/MC Good 
40.  9420 Nandhini 09/FC Good 
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PATIENTS PHOTOS 
 
1. Op No. 9421 (9yrs/fc)     
 
                 
         Before treatment                                       After treatment 
 
 
 
 
2. Op No. 9062 (8yrs/mc)     
 
            
 
         Before treatment                             After treatment 
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RESULTS 
S.NO RESULTS NO: OF CASES PERCENTAGE 
1. Good 25 62.5 % 
2. Moderate 10 25 % 
3. Mild 5 12.5% 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inference 
 Among 40 patients 25 (62.5%) cases showed good improvement, 10 (25%) 
cases showed moderate improvement, 5 (12.5%) cases showed mild improvement. 
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LABORATORY INVESTIGATION REPORT OF THE PATIENTS 
 
 
 
 
 
 
S.NO 
       
     
   
 
         NAME 
 
 
 
OP. 
NO 
 
 
 
AGE/ 
SEX 
                         HEMATOLOGICAL ANALYSIS    
    Hb 
(gms%) 
                
          URINE ANALYSIS         BEFORE  TREAATMENT          AFTER TREATMENT 
TC         DC ESR 
mm 
TC           DC ESR mm BT AT            BT         AT 
P 
% 
L% E% ½ 
hr 
1 
hr 
P% L% E% ½ 
hr 
1 
hr 
Alb Sug Dep Alb Sug dep 
1.  DHINAKARAN 9062 08/MC 9200 60 35 5 7 18 9000 65 30 3 5 10 11.5 10.8 N N N N N N 
2.  NITHYA 9421 09/FC 4400 61 30 9 5 12 6900 60 28 5 4 8 10.3 11.5 N N N N N N 
3.  NANDINI 9420 09/FC 8100 53 38 9 4 8 7200 59 32 3 4 05 11.5 10.9 N N N N N N 
4.  SABITHA 8918 61/2/FC 10900 41 51 8 4 12 11000 50 45 1  4 10 11.1 11.5 N N N N N N 
5.  SAI GANESH 6197 06/MC 7700 53 39 8 9 15 8700 59 29 1 5 10 09.2 10.5 N N N N N N 
6.  MAHATH 3198 08/MC 12100 79 17 6 3 8 11000 65 30 4 3 8 12.0 11.5 N N N N N N 
7.  PRATHIKSHA 6135 12/FC 7300 48 45 7 3 10 8100 50 40 5 5 9 12.9 12.5 N N N N N N 
8.  DINESH 8674 12/MC 8400 50 45 5 28 42 8900 55 42 3 10  15 11.7 11.9 N N N N N N 
9.  NITHYA 0787 07/FC 6000 56 39 5 8 15 7200 52 42 2 4 8 10.4 11.2 N N N N N N 
10.  YOGESHWARAN 5192 09/MC 7700 55 39 6 23 40 8900 65 40 3 15 25 11.6 12.0 N N N N N N 
11.  DHARSHINI 3214 08/FC 11300 29 63 8 10 26 10000 50 40 7 9 24 09.9 11.0 N N N N N N 
12.  KAVIYA SRI 1678 08/FC 10000 77 28 5 12 25 9600 70 28 3 4 12 07.1 10.2 N N N N N N 
13.  YUGASHINI 4740 10/FC 10500 58 35 7 14 25 9900 50 30 5 5 20 12.1 12.5 N N N N N N 
14.  GANESH 5985 08/MC 8900 54 40 6 25 42 8800 50 48 3 5 10 13.1 12.2 N N N N N N 
15.  DHANUSKA 5846 08/FC 7500 66 28 6 4 10 8000 68 30 5 3 9 12.4 11.5 N N N N N N 
16.  PREETHA 1474 08/FC 8600 77 17 6 8 20 9000 79 20 4  5 15 12.9 12.0 N N N N N N 
17.  MANJU 7000 08/FC 10600 58 36 6 2 6 11200 60 30 7 2 8 08.6 10.2 N N N N N N 
18.  KAVIYA 5984 07/FC 10800 58 30 8 2 8 10900 50 48 2 3 5 08.8 10.8 N N N N N N 
19.  MANIKANDAN 4868 11/MC 6300 59 34 7 4 9 8200 60 35 4 4 8 13.4 12.5 N N N N N N 
20.  DHIYA 5706 12/FC 8300 53 38 9 5 12 8900 60 40 5 4 10 11.9 12.0 N N N N N N 
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LABORATORY INVESTIGATION REPORT OF THE PATIENTS 
 
 
 
 
 
S.NO 
 
 
         
           NAME 
 
 
OP. 
NO 
 
 
AGE/ 
SEX 
                         HEMATOLOGICAL ANALYSIS Hb 
(gms%) 
        
               URINE ANALYSIS          BEFORE  TREAATMENT       AFTER TREATMENT 
TC         DC ESR mm TC           DC ESR  BT AT       BT       AT 
P% L% E% ½ 
hr 
1 
hr 
 P% L% E% ½ 
hr 
1 
hr 
  Alb Sug Dep Alb Sug dep 
21.  ARVINI 3197 07/FC 8100 68 25 7 6 15 8900 65 32 3 04 08 12.1 11.5 N N N N N N 
22.  GATHSOPH 0775 09/MC 8900 45 47 8 22 42 8800 40 57 3 05 10 08.0 10.2 N N N N N N 
23.  LABISHA 8013 06/FC 9900 37 53 10 05 15 9200 45 52 3 04 10 13.1 12.5 N N N N N N 
24.  MUHAMMED 
KHAN 
7750 61/2/MC 10100 45 49 6 06 15 8900 49 45 4 08 12 12.2 12.0 N N N N N N 
25.  SAI DHARSHINI 5847 10/FC 8100 70 24 6 03 12 8800 65 32 3 03 10 12.3 12.5 N N N N N N 
26.  DHARSHINI 
PRIYA 
0711 08/FC 6400 46 47 7 08 15 7500 56 42 3 04 10 12.2 12.2 N N N N N N 
27.  ALKALF 8687 06/MC 10700 69 24 7 14 20 10900 65 30 5 05 10 14.3 13.2 N N N N N N 
28.  ILA MUKILAN 3025 06/MC 7100 43 45 9 05 15 8900 45 50 5 04 10 12.4 11.5 N N N N N N 
29.  YOGESH 8963 10/MC 12800 71 24 5 26 40 11600 62 34 4 05 10 13.4 12.5 N N N N N N 
30.  DHARNIKA 9338 06/FC 8800 62 33 5 03 05 8000 58 38 3 02 04 12.7 12.0 N N N N N N 
31.  SAMRITHA 4705 12/FC 8100 67 29 4 07 18 8900 65 32 2 05 10 11.3 11.2 N N N N N N 
32.  KAJAN 
KARTHICK 
6994 06/MC 8900 36 56 8 22 42 9200 46 48 4 05 12 11.8 11.5 N N N N N N 
33.  SRI NISHA 6999 07/FC 8200 40 55 5 12 25 8500 50 40 8 10 20 11.6 11.2 N N N N N N 
34.  SUDHA 1896 08/FC 6800 46 48 6 21 39 7200 50 48 2 08 12 16.0 15.0 N N N N N N 
35.  AKSHAYA 9337 10/FC 9100 51 41 8 05 12 9800 57 40 2 03 10 11.2 12.0 N N N N N N 
36.  AYEESH 8014 08/MC 7200 54 41 5 10 18 7200 54 41 5  10 15 12.5 11.9 N N N N N N 
37.  VIGNESH 
WARAN 
8045 81/2/MC 5300 72 22 6 03 08 6900 62 32 3 03 06 09.0 10.2 N N N N N N 
38.  MATHAN 
KUMAR 
2040 11/MC 11100 58 34 8 15 35 10800 50 46 3 05 10 11.2 10.8 N N N N N N 
39.  PRASANTH 7301 06/MC 9900 54 39 7 07 18 8900 50 42 4 05 12 11.8 10.8 N N N N N N 
40.  DHIVYA 
LAKSHMI 
5749 11/FC 8300 58 37 5 12 25 9800 60 38 2 06 12 12.0 12.5 N N N N N N 
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EASI SCORE 
 
ECZEMA AREA AND SEVERITY INDEX (EASI): 
  
R - Redness   T - Thickness     
S - Scratching                          L - Lichenification 
 
EASI=0.1(EH+TH+SH+LH)AH+0.2(EU+TU+SU+LU)AU+0.3(ET+TT+ST+LT)AT+0.4(EL+TL
+SL+LL)AL 
 
Redness/ Thickness/Scratching/Lichenification scoring:              AreaScoring: 
           
   
0 - Nil         0-Nil  
1- Mild    1-1-9% 
2- Moderate    2- 10-29% 
3-Severe    3-30-49%               
    4-50-69%  
    5-70-89%   
         6-90-100% 
 
Easi score: 
0  -clear 
0.1 to 5.9 -mild 
6.0 to 22.9 -moderate 
23.0 to 72 -severe 
 
S.NO OP.NO                               DETAILS       SYMPTOMS 
SCORE 
           NAME AGE/SEX    BEFORE AFTER 
1)  5749 DHIVYA LAKSHMI 11/Fc 09.8 0.1 
2)  9337 AKSHAYA 10/Fc 15.2 2.0 
3)  8014 AYEESH 08/Mc 22.0 1.6 
4)  6197 SAI GANESH 06/Mc 12.0 0.1 
5)  5192 YOGESHWARAN 09/Mc 24.0 2.0 
6)  1474 PREETHA 08/Fc 04.2 0.0 
7)  5846 DHANUSHKA 08/Fc 16.2 0.1 
8)  5106 DHIVYA  12/Fc 09.8 0.0 
9)  9421 NITHYA  09/Fc 19.8 0.1 
10)  4740 YUGASHNI  10/Fc 16.2 0.1 
11)  6135 PRATHIKSHA  12/Fc  18.8 6.2 
12)  3214 DHARSHINI  08/Fc 22.4 6.0 
13)  8918 SAHITHA  61/2 /Fc 15.2 4.8 
14)  7000 MANJU  08/Fc 16.2 5.2 
15)  6999 SRI NISHA  07/Fc 10.8 6.2 
16)  0775 GATHSOPH  09/Mc 12.0 0.0 
17)  9062 DHINAKARAN  08/Mc 07.2 0.0 
18)  9338 DHARNIKA  06/Fc 15.2 0.0 
19)  7301 PRASANTH  06/Mc 16.0 0.0 
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20)  9420 NANDHINI  09/Fc 09.8 0.0 
21)  8013 LABISHA  06/Fc 12.0 0.0 
22)  3197 ASHWINI  07/Fc 16.2 0.0 
23)  4868 MANIKANDAN  11/Mc 09.8 0.0 
24)  8687 ALKAIF  06/Mc 07.2 2.0 
25)  5985 GANESH  08/Mc 15.2 0.0 
26)  3198 MAHATH  08/Mc 21.6 0.0 
27)  5847 SAI DHARSHINI  10/Fc 18.0 0.0 
28)  5984 KAVIYA  07/Fc 22.4 0.0 
29)  7750 MUHAMMED KHAN 61/2/Mc 16.4 0.0 
30)  4705 SAMRITHA  12/Fc 09.6 0.0 
31)  3025 ILA MUKILAN 06/Mc 12.0 0.0 
32)  8674 DHINESH  12/Mc 26.0 0.0 
33)  0711 DHARSHINI PRIYA  08/Fc 09.8 0.0 
34)  8045 VIGNESHWARAN  81/2/Mc 16.2 2.0 
35)  6994 KAJAN KARTHIK 06/Mc 07.2 0.0 
36)  8963 YOGESH  10/Mc 09.6 0.0 
37)  0787 NITHYA  07/Fc 04.0 0.0 
38)  2040 MATHAN KUMAR 11/Fc 04.0 0.0 
39)  1678 KAVIYA SRI 08/Fc 18.0 0.0 
40)  1896 SUDHA  08/Fc 06.6 0.0 
 
       MC – MALE CHILD 
       FC – FEMALE CHILD 
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DISCUSSION 
 
Bala karappan is a common skin disease in paediatric age group. This disease 
mostly resembles Atopic dermatitis in modern system. It is a chronic relapsing 
pruritic inflammatory skin disease in children associated with personal or family 
history of other atopic dermatitis like asthma, allergic rhinitis. Symptoms of atopic 
dermatitis are dryness, erythema, excoriation, exudation, fissuring, hyperkeratosis, 
lichenification, papulation, scaling and vesiculation .In this study 40 cases are treated 
in OPD of postgraduate department of Kuzhanthai Maruthuvam in Govt. Siddha 
Medical College, attached to Arignar Anna Hospital of Indian Medicine, Chennai-106 
from 2016 -2019. 
The patients were examined on siddha system of diagnosis with the help of 
modern investigations. The patients are treated with the trial drug Saaranai ennai 
(Internal & External) for 21 days.  
 The observations are described here.  
1. Sex Distribution: 
Among the 40 cases 23 patients were female children and 17 patients were 
male children. Mostly female children were affected. 
2. Age Distribution:  
Among the 40 cases, maximum numbers of patients 72.5% were in the age 
group of 6 to 9 years, 27.5% were in the age group of 9 to 12 years  
3. Socio Economic status  
Among the 40 cases, maximum numbers of patients 60% were in poor status, 
35% were in middle class and 5% were in high class .The highest incidence was 
observed in poor class children due to poor hygienic, mal nutrition , exposure to 
polluted environment lower their immune response , so the poor children are more 
prone to the disease.  
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4. Family History  
               Among the 40 cases, 60% of the patients showed negative family history, 
40% patients showed positive family history. 
5.  Dietary Habits  
             Among the 40 cases, 90% of the cases were mixed diet, 10% of cases were 
vegetarians. 
6. According to Paruvakalam  
Among the 40 cases, 25% cases were observed in Munpanikalam, 32.5% of 
cases in Koothirkalam, 10% cases in kaarkalam and elavenil kalam and 22.5% of 
cases observed in pinpanikalam. This study shows dryness of the skin due to cold 
climate may cause the skin diseases in this season .  
7. Distribution of Thinai  
 Out of 40 cases, highest incidence 100% of cases were from in Neithal 
thinai.This is due to the fact that the study was conducted at Chennai a Neithal land 
and so majority of the cases were from that land. As per siddha literature kabam   is 
affected in neithal nilam so it may aggravate the skin diseases.  
8. Uyir Thathukkal  
Vatham  
Among the 40 cases, Vyanan and Samanan was affected in 100% patients, 
Udhanan was affected in 30% of patients, Devadhathan was affected in 25% of 
patients, Abanan was affected in  12.5% of patients and Kirukaran was affected in   
12.5% of patients, Pranan was affected in 12.5% of patients. . 
Pitham 
Among the 40 cases,Prasaga pitham was affected in 40 patients. Anarpitham 
was affected in 12.5% of the patients and ranjaga pitham was affected in 82.5% of 
the patients. Prasaga pitham is responsible for complexion of the skin so it was 
affected in all cases(100%) .  
 
Kabam 
Out of 40 cases, Kilethagam and Avalambagam was affected  12.5% of the 
patients. 
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9. Udal thathukkal  
Out of 40 patients Saaram  was affected in  all  the cases, Seneer was affected 
in 33 (82.5%) cases  and Oon was affected in 10 (25%)cases.  
10. Ennvagai Thervugal  
Out of 40 patients, Niram and Sparisam were affected in all the cases, Naa   
were affected in 82.5% of cases and Malam were  affected in 12.5% of the patients .In 
this study 65% of patients have Vatha Pitha Naadi and 35% patients have Pitha Vatha 
Naadi.  
11. Neikuri 
          Among the 40 cases, 25% of patients were having Vatha neer, 25% of patients 
were having Pitha neer and 50% of patients were having Kaba neer.  
12. Clinical Features 
Among the 40 patients. 100% of cases have itching, papules, and 
hyperpigmentation 95%  of cases have erythema, 52.5% have scaling, Oozing and 
Lichenification  have 47.5%, 50% have vesicles 12.5% have ulcer. After treatment  
5%  of cases have Ulcer, 10% of cases have Itching, 0ozing and Papules,12.5% cases 
have  Scaling and Vesicles, 15% cases have  Erythema and 22.5% of cases have 
lichenification. 
13. Lab investigation 
Routine examination of blood and urine were done before and after treatment. 
In most of the cases (85%) were having elevated ESR and increased eosinophil count 
and it has decreased after treatment. 
14.Biochemical analysis  
Qualitative analysis of the Saaranai ennai in the presence of iron which is 
more soluble and readily absorbable from that helps treating children who have 
associated anaemia. The study also indicates the presence of chloride.      
15. Toxicity study of the drug:  
The Acute and Sub-acute toxicity of the trial drug was carried out in Wistar 
albino rats reveals that the drug has no adverse effects, so it is safe to human beings. 
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16. Physicochemical analysis:  
Saaranai ennai:         
Viscosity at 50
o
C (Pa s) : 77.17 
Refractive index  : 1.32 
Weight per ml (gm/ml) : 0.087 
Iodoine value (mg I2/g) : 95.25 
Saponification Value 
(mg of KOH to saponify 1gm of fat) 
: 174.8 
Acid value mg KOH/g : 1.047 
Peroxidase value mEq/kg : 4.987 
 
 
17. Pharmacological analysis:  
Pharmacological analysis showed the internal drug has significant Anti- 
histamine activity. 
18. Statistical Analysis  
 Since the p value is significant in all clinical features. So there is 
significant reducing of clinical features among the patients for the treatment of Bala 
Karappan (Atopic Dermatitis). Hence it is concluded that the treatment was 
effective and significant. 
19. Result 
 Among the 40 patient’s good improvement is observed in 25 cases (62.5%), 
moderate improvement in 10 cases (25%) and mild improvement in 5cases (12.5%) 
and no adverse events observed clinically during the course of treatment.  
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SUMMARY 
The clinical study was conducted with the trail drug saaranai ennai as Internal 
& external medicine for the disease Bala karappan in children. 40 patients were 
selected based on protocol. The study is conducted after being screened by the 
screening committee and approved by the Institutional  Ethics committee(IEC) of 
Govt siddha medical college, chennai.  Animal studies are carried, Hence, the study is 
safely executed on human volunteer patients and there was no adverse drug reactions 
noted during the study period. 
40 children with Bala karappan diagnosed clinically treated in out patient 
department  of Arignar Anna Hospital of Indian Medicine, Chennai-106.  They were  
under gone laboratory investigation treated with trial drug, observed for clinical 
improvement and any adverse reaction of the drug . 
I like to summarize this clinical study by the following: 
  The efficacies of the trial drug saaranai ennai were studied and observed in 
this study. 
 Clinical diagnosis of Bala karappan was done on the basisof clinical features 
described in Kuzhanthai maruthuvam (Bala vagadam) and Noi muthal  nadal 
thirattu. 
 The cost of the trial medicines are low, comparatively economic. These drugs 
are easily available and the dosage is also convenient. 
 The potency of the trial drug reveals that the presence of chloride, Iron, 
flavonoids, glycosides, steroids, carbohydrates, triterepnoids, coumarins, 
phenols, saponins.      
 The physico chemical analysis of the trial drug shows the safe and 
effectiveness of the drug with the following:  
Viscosity at 50
o
C (Pa s) : 77.17 
Refractive index  : 1.32 
Weight per ml (gm/ml) : 0.087 
Iodoine value (mg I2/g) : 95.25 
Saponification Value 
(mg of KOH to saponify 1gm of fat) 
: 174.8 
Acid value mg KOH/g : 1.047 
Peroxidase value mEq/kg : 4.987 
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The pharmacological analysis of the drug reveals that it possesses very good  
acute and chronic anti histamine and immuno modulatory activity. 
Among the 40 cases treated 62.5% cases had shown Good improvement, 25% 
cases had shown Moderate improvement, 12.5% had shown Mild 
improvement.  
Observation made during the clinical study showed that the trial drug was 
clinically effective and has no adverse reaction among children. 
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CONCLUSION 
 Bala karappan is a common skin disorder  in children and mainly caused by 
derangement of kabha kuttram followed by vatham and pitham. In this clinical study 
“Saaranai ennai” was taken as internal & External drug respectively. The deranged 
kuttram is settled down by the kaippu suvai  and inipu suvai present in the trial 
medicine Saaranai ennai  (Internal & External medicine) there by the medicine acts as 
Ethirurai maruthuvam to cure the disease. 
Toxicological studies shows no acute  and sub acute toxicity of the drug. The 
drug has Anti-Histamine activity. 
 The cost of the trial medicines are low. 
 During the clinical study no adverse events were observed.  
The clinical study confirms the efficacy of the trial drugs by reducing the 
clinical signs and symptoms like itching, Papules, Oozing and scaling. . Clinical study 
results found to be Good in 62.5% cases, Moderate in 25% cases, and Mild in 12.5% 
cases. The Clinical trial conducted in selected patients was satisfactory and 
encouraging. The trial medicine is effective for Bala karappan in children. Through 
this study, the effectiveness of trial drug is confirmed and re-established by the 
author. 
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BIO STATISTICAL ANALYSIS 
 
 The most popular non parametric statistical tool, namely McNemat test 
analysis has been employed to analyse the effectiveness with the help of a hypothesis. 
 
S.NO Clinical features 
Before Treatment After Treatment 
No.of 
cases 
Percentage 
No.of 
cases 
Percentage 
1 Itching 40 100% 4 10% 
2 Vesicles 20 50% 5 12.5% 
3 Oozing 19     47.5% 4 10% 
4. Papules 40   100% 4 10% 
5 Scaling 21 52.5% 5 12.5% 
6 Erythema 38 95% 6 15% 
7 Hyperpigmentation 40 100% 10 25% 
8 Ulcer 5 12.5% 2 5% 
9 Lichenification 19 47.5% 9 22.5% 
 
Mc nemat test, C.I: 95%, 
*
P<0.05; **,0.01 
 
Software: spss 20 version 
Number of cases: 40 
Inference:  
 Since the p value is significant in all clinical features. So there is significant 
reducing of clinical features among the patients for the treatment of BALA 
KARAPPAN (Atopic dermatitis). Hence it is concluded that the treatment was 
effective and significant. 
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GOVERNMENT  SIDDHA  MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
CLINICAL STUDY ON “SAARANAI ENNAI (INT & EXT)” IN THE 
TREATMENT OF 
“BALA KARAPPAN’’ (ATOPIC DERMATITIS)   IN CHILDREN 
1. OP NO  : ………………… 
FORM l - SCREENING AND SELECTION PROFORMA 
2. NAME  : …………………  
3. AGE  : …………………        
4. GENDER  : ………………… 
5. F.OCCUPATION : …………………       
6. F.INCOME : ………………… 
7. ADDRESS  : …………………  
………………… 
………………… 
8. CONTACT NO : …………………              
 INCLUSION CRITERIA: 
• Age :  6-12 Yrs       Yes / No 
• Itching                   Yes / No 
• Patient having symptoms of erythema,vesicles, oozing.  Yes/No 
• Patient having symptoms of  lichenification    Yes/No 
• Patients who are willing to undergo  Laboratory  investigation. Yes / No 
• Patients who are willing to sign the informed consent stating that he/ she will 
conscientiously  stick to the treatment during 48days but can opt out of the 
trial of his/ her own conscious discretion.     Yes 
/ No 
 
 
 
EXCLUSION CRITERIA 
(Clinical history) 
• History of  scabies 
• History of  photo dermatitis 
• History of  secondary bacterial infection 
• History of furunculosis 
 
ADMITTED TO TRIAL: 
 YES                        NO                 
    If yes,             OPD/IPD                    
 
 
Date:        
Station: 
 
 
 
Signature of the Guide                                                  Signature of the Investigator   
 
 
 
 
 
GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI-600 106 
CLINICAL STUDY ON “SAARANAI ENNAI (INT & EXT)” IN THE 
TREATMENT OF“BALA KARAPPAN’’ (ATOPIC DERMATITIS)  IN 
CHILDREN 
 
FORM lI -HISTORY TAKING PROFORMA 
1. SERIAL NO OF THE CASE : 
2. OP/IP NO   : 
3. NAME    : 
4. AGE    : 
5. GENDER   : 
6. F. OCCUPATION  : 
7. INCOME   : 
8. COMPLAINTS & DURATION:   
 
 
9. PERSONAL HISTORY : 
 
 
10. HISTORY OF PREVIOUS ILLNESS 
 
 
11. BIRTH HISTORY 
 
 
 
12. DIETARY HABIT :     
 
• Vegetarian              
• Non-vegetarian 
 
13. FAMILY HISTORY : 
               Whether this problem runs in family? 
  1. Yes                               2.No         
               If yes, mention the relationship of affected person(s) --------------------- 
               History of previous investigations if any ------------------------------ 
 
 
Date:          
Station                                               
 
 
Signature of the Guide                                            Signature of the Investigator 
 
 
 
GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
CLINICAL STUDY ON “SAARANAI ENNAI (INT & EXT)” IN THE 
TREATMENT OF 
“BALA KARAPPAN’’ (ATOPIC DERMATITIS) IN CHILDREN 
 
FORM III- CLINICAL ASSESSMENT PROFORMA 
1. SERIAL NO : …………………………. 
2. OP / IP NO : ………………………….  
3. NAME  : …………………………. 
4. AGE  : …………………………. 
5. GENDER : …………………………. 
GENERAL EXAMINATION: 
Height (cms)                : ………………………….                   
Weight (kg)    : ………………………….                   
Temperature(°F)     : ………………………….                   
Pulse rate(/min)   : ………………………….                   
Heart rate(/min)   : ………………………….                   
Respiratory rate(/min)  : ………………………….                   
Blood pressure(mm/Hg)       : ………………………….           
   Present           Absent 
Pallor  
Jaundice 
Cyanosis 
Lymphadenopathy 
Pedal edema 
 
 
Clubbing 
Jugular vein pulsation 
SYSTEMIC EXAMINATION 
CardioVascular System  : ………………………….                   
 
Respiratory system   : ………………………….                   
 
Gastro-intestinal system  : ………………………….                   
 
Central Nervous System  : ………………………….                   
 
Urogenital system   : ………………………….                   
 
Endocrine System   : ………………………….                   
SIDDHA SYSTEM OF EXAMINATIONS: 
1. THEGI:  [BODY CONSTITUTION]  
1. Vathaudal 
2. Pithaudal 
3. Kabaudal 
4. Thon  
2. NILAM:  [LAND WHERE PATIENT LIVED MOST] 
 1. Kurinji (Hilly terrain)                                   
 2. Mullai (Forest range)                       
 3. Marutham (Plains)                            
 
 
4. Neithal (Coastal belt)             
 5. Paalai (Arid regions) 
3. KAALAM: 
1. Kaarkaalam  4.Pinpani kaalam 
2. Koothirkaalam  5. Ilavenilkaalam 
3. Munpanikaalam  6.Muthuvenil kaalam 
4. GUNAM: 
 1.Sathuvam 2.Raasatham             3.Thaamatham 
5. IMPORIGAL (SENSORY ORGANS): 
Normal/Affected 
Mei  _____________________________ 
Vaai _____________________________ 
Kann  _____________________________ 
Mukku _____________________________ 
Sevi  _____________________________ 
6. KANMENDHIRIYAM (MOTOR ORGANS): 
Kai  _____________________________ 
Kal  _____________________________ 
Vaai  _____________________________ 
Eruvai _____________________________ 
Karuvaai _____________________________ 
7. KOSANGAL (SHEATH): 
Annamayakosam ______________________ 
Pranamayakosam ______________________ 
Manomayakosam ______________________ 
Vignanamayakosam_____________________ 
Anandamayakosam ______________________
 
 
8. UYIR THAATHUKKAL: [THREE HUMORS] (VALI,  AZHAL, IYAM) 
A) VALI 
Pranan ______________________ 
Abanan ______________________ 
Samanan ______________________ 
Uthanan ______________________ 
Vyanan ______________________ 
Naagan ______________________ 
Koorman ______________________ 
Kirukaran ______________________ 
Devathathan ______________________ 
Dhananjayan ______________________ 
B) AZHAL 
Analakam ______________________ 
Ranjakam ______________________ 
Sathakam ______________________ 
Prasakam ______________________ 
Alosakam ______________________ 
C) IYAM 
Avalambagam ______________________ 
Kilethagam  ______________________ 
Pothagam  ______________________ 
Tharpagam  ______________________ 
Santhigam  ______________________ 
 
 
9. SEVEN UDAL THATHUKKAL: (SEVEN SOMATIC COMPONENTS) 
Saram ______________________ 
Senneer ______________________ 
Oon  ______________________ 
Koluppu ______________________ 
Enbu  ______________________ 
Moolai______________________ 
Sronitham ______________________ 
10. ENVAGAI THERVU: 
I. NAADI : [PULSE PERCEPTION] 
II. SPARISAM : [PALPATION] 
III. NAA : [TONGUE] 
 IV.NIRAM : [COMPLEXION]   
 1. Vadham 
 2. Pitham 
 3. Kabam 
 V.MOZHI: [VOICE] 
1. High Pitched 
            2. Low Pitched 
 3. Medium Pitched 
VI.VIZHI : [EYES] 
 
 
VII. MALAM: [BOWEL HABITS / STOOLS] 
Niram 
Irugal 
Ilagal 
Others 
 VIII. MOOTHIRAM [URINE EXAMINATION]   
NEERKKURI: 
Niram 
Manam 
Edai 
Nurai 
Enjal 
NEIKKURI 
 
 
Date:      
Station: 
 
 
Signature of the Guide                                        Signature of the Investigator   
 
 
 
 
GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
POST- GRADUATE DEPARTMENT OF  KUZHANTHAI MARUTHUVAM 
CLINICAL STUDY ON “SAARANAI ENNAI (INT & EXT)” IN THE 
TREATMENT OF 
“BALA KARAPPAN’’ (ATOPIC DERMATITIS)   IN CHILDREN 
 
FORM IV : LABORATORY INVESTIGATIONS PROFORMA 
1. SERIAL NO OF THE CASE : ______________________   
2. OP / IP NO   : ______________________   
3. NAME    : ______________________   
4. AGE    : ______________________      
5. GENDER   : ______________________   
A) BLOOD INVESTIGATIONS: 
BLOOD INVESTIGATIONS BEFORE 
TREATMENT 
AFTER 
TREATMENT 
Hb ( gm/dL)   
Absolute eosinophil count ( Cells/ul)   
           ESR (mm) ½ hr.   
 1 hr.   
           T.WBC (Cells / Cu.mm)   
Differential 
Count (%) 
Polymorphs   
 Lymphocytes   
 Monocytes   
 Eosinophils   
 Basophils   
 
 
 
 
B) URINE INVESTIGATIONS: 
URINE 
INVESTIGATIONS 
BEFORE TREATMENT AFTER TREATMENT 
Albumin   
Sugar   
Deposits   
 
 
 
Date:          
Station: 
 
 
 
Signature of the Guide                     Signature of the Investigator   
 
 
 
 
 
GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
CLINICAL STUDY ON “SAARANAI ENNAI (INT &EXT )” IN THE 
TREATMENT OF“BALA KARAPPAN’’ (ATOPIC DERMATITIS)  IN 
CHILDREN 
 
FORM V: INFORMED CONSENT FORM 
“I have read the foregoing information, or it has been read to me. I have 
had the opportunity to ask questions about it  to my satisfaction. 
            I   consent voluntarily to participate my chid in this study and understand 
that I have the   right to withdraw my child from the study at any time without in 
any way it affecting my chid further medical care”. 
"I have received a copy of the information sheet/consent form". 
Date: 
Signature of the participant: 
In case of illiterate participant 
  “I have witnessed the accurate reading of the consent form to the potential 
participant, and the individual has had the opportunity to ask questions. I confirm 
that the individual has given consent freely.”                                                   
Date: 
Signature of a witness                               Left thumb Impression of the Participant     
(Selected by the participant bearing no connection with the survey team)       
Date:    
Station:                                                                                  
Signature of participant:                                                 
 
Signature of the Guide:                                            Signature of the Investigator:   
 
 
muRrpj;jkUj;Jtf; fy;Y}Hp> nrd;id-106 
mwpQh; mz;zhkUj;Jtkid>nrd;id 
 
ghyfug;ghd; Neha;f;fhdrpj;jkUe;jpd; (rhuizvz;nza;) 
 
 ghpfhpg;Gj; jpwidf; fz;lwpAk; kUj;JtMa;tpw;fhdjfty; gbtk; 
Xg;Gjy; gbtk; Ma;thsuhy; rhd;wspf;fg;gl;LJ. 
ehd; ,e;jMa;itFwpj;jmidj;Jtpguq;fisAk; Nehahspf;FGupAk; tifapy; 
vLj;Jiuj;Njd; vdcWjpaspf;fpNwd;. 
Njjp:                            ifnahg;gk;: 
,lk;:                            ngah;:  
Nehahspapd; ngw;Nwhh; xg;Gjy; gbtk;  
vd;dplk; ,e;jkUj;JtMa;tpd; fhuzj;ijAk;>kUe;jpd; jd;ikkw;Wk; 
kUj;JttopKiwgw;wpAk;>njhlh;e;JvdJcly; 
,af;fj;ijfz;fhzpf;fTk;>mjidghJfhf;fTk; gad;gLk; kUj;JtMa;Tf;$l 
ghpNrhjidfs; gw;wpjpUg;jpmspf;Fk; tifapy; Ma;TkUj;Jtuhy; tpsf;fpf; 
$wg;gl;lJ. 
ehd; vdJFo;e;ijapd; ,e;jkUj;JtMa;tpd; NghJfhuzk; vJTk; 
$whky;>vg;nghOJNtz;LkhdhYk; 
,e;jMa;tpypUe;JvdJFoe;ijiatpLtpj;Jnfhs;Sk; 
cupikianjupe;jpUf;fpd;Nwd;. ehd; vd;DilaRje;jpukhfNjh;Tnra;Ak; 
cupikiaf; nfhz;LNeha;f;fhdrpw;whKl;bnea; kUe;jpd; ghpfhpg;Gk; jpwidf; 
fz;lwpAk; kUj;JtMa;tpw;Fvd;idcl;gLj;jxg;Gjy; mspf;fpNwd;.  
Njjp:                            ifnahg;gk;: 
,lk;:    ngah;:  
Njjp:                            rhl;rpf;fhuh; ifnahg;gk;: 
,lk;:                            ngah;:  
cwT: 
 
 
Jiwj;jiyth; ifnahg;gk;:          Muha;r;rpahsh; ifnahg;gk;: 
 
 
GOVERNMENT SIDDHA MEDICAL COLLEGE, CHENNAI 
CLINICAL STUDY ON “SAARANAI ENNAI” IN THE TREATMENT OF 
“BALA KARAPPAN’’ (ATOPIC DERMATITIS) IN CHILDREN 
SI NO       : 
FORM VI - WITHDRAWAL FORM 
OP / IP NO      :                                               
NAME      : 
AGE / GENDER      :                
DATE OF TRIAL COMMENCEMENT  : 
DATE OF WITHDRAWAL FROM TRIAL : 
REASONS FOR WITHDRAWAL: 
• Long absence at reporting    Yes/ No 
• Irregular treatment     Yes/ No 
• Shift of locality      Yes/No 
• Increase in severity of symptoms   Yes/No 
• Development of severe adverse drug reactions Yes/No 
 
 
Date:          
Station: 
 
 
Signature of the Guide                                                 Signature of the Investigator 
    
 
 
GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
CLINICAL STUDY ON “SAARANAI ENNAI” IN THE TREATMENT OF 
“BALA KARAPPAN’’ (ATOPIC DERMATITIS)  IN CHILDREN 
 
FORM VII – PATIENT INFORMATION SHEET 
Name of Co- Investigator:T.Swathini 
Name of the college:Govt.SiddhaMedical  College, Arumbakkam, Chennai-106. 
INFORMATION SHEET FOR PATIENTS PARTICIPATING IN THE OPEN 
CLINICAL TRIAL. 
 I,T.SWATHINI studying M.D (Siddha) at Govt.Siddha Medical College, Chennai, is 
doing a clinical trial on ‘‘Balakarappan” – (Atopic dermatitis)in children . It is becoming a 
most common disease, occurring throughout the world. In this regard, I am in need to ask you 
few questions. I will maintain confidentiality of your comments and data obtained. There will 
be no risk of disclosing your identity and no physical, psychological or professional risk is 
involved by taking part in this study. Taking part in this study is voluntary. No compensation 
will be paid to you for taking  part in this study. 
           You can choose not to take part. You can choose not to answer a specific question. 
There is no specific benefit for you if you take part in the study. However, taking part in the 
study may be of benefit to the community, as it may help us to understand the problem of 
defaulters and potential solutions. 
             If you agree to be a participant in this study, you will be included in the study 
primarily by signing the consent form and then you will be given the internal medicine 
“saaranaiennai”(Internal & External medicine) 1-2 ml(INT) and 30 ml(EXT) for 21 days.  
 The information I am collecting in this study will remain between you and the Co- 
investigator (myself). I will ask you few questions through a questionnaire. I will not write 
your name on this form. I will use a code instead. 
The questionnaire will take approximately 20 minutes of your time. 
If you wish to find out more about this study before taking part, you can ask me all 
the questions you want or contact T.Swathini, PG Scholar cum Co- investigator of this study, 
attached to Govt. Siddha Medical College, Chennai-106. You can also contact the Member-
secretary of Ethics committee, Govt.Siddha Medical College, Chennai. 
 
 
muRrpj;jkUj;Jtf; fy;Y}Hp> nrd;id-106 
mwpQh; mz;zhkUj;Jtkid>nrd;id 
ghyfug;ghd;  Neha;f;fhdrpj;jkUe;jpd; (rhuizvz;nza;) 
ghpfhpg;Gj; jpwidf; fz;lwpAk; kUj;JtMa;tpw;fhdjfty; gbtk; 
Muha;r;rpahsh; ngau;: kUj;Jth;.jp.Rthjpdp 
epWtdj;jpd; ngau;:muRrpj;jkUj;Jtf; fy;Y}up>mUk;ghf;fk;>nrd;id-106 
muRrpj;jkUj;Jtf; fy;Y}upapy; gl;lNkw;gbg;Ggapd;WtUk; ehd; 
kUj;Jtu;  
jp.Rthjpdpghyfug;ghd; vd;Dk; Nehapy; kUj;JtMuha;r;rpapy; 
<Lgl;Ls;Nsd;. 
 ,e;j Neha;  guk;giuahfTk; 
xt;thjczTg;nghUl;fiscl;nfhs;tjhYk;  xt;thikiaVw;gLj;Jk; 
nghUl;fspd; Nky; mbf;fbcuha;tjpdhYk; cz;lhfpwJ. ,Jgutf; 
$baNehay;y. 
 ,e;jMuha;r;rprk;ge;jkhfrpyNfs;tpfisf; Nfl;fTk;>NjitahdMa;tfg; 
gupNrhjidf;Fjq;fs; Foe;ijiacl;gLj;jTkcs;Nsd;. 
  ,e;jMuha;r;rpf;Fjq;fs; tpUg;gj;jpd; Ngupy; cl;gLk; gl;rj;jpy; 
cs;kUe;ehfrhuizvz;nza; 1-2kpypkw;Wk; ntspkUe;jhf 30kpy;yp 
gad;gLfpd;wJ. 
 ,e;jkUe;Jrpwg;ghfghz;LNeha;f;fhfmq;fPfupf;fg;gl;lrpj;jkUj;Jt E}ypy; 
$wg;gl;Ls;sJ 
 ,e;jMuha;r;rpapy; jq;fismDkjpj;jgpwFcq;fSf;FtpUg;gk; 
,y;iynadpy; vg;NghJNtz;LkhdhYk; Muha;r;rpapy; ,Ue;Jtpyfpf; 
nfhs;scupikcs;sJ. 
 ,e;jMuha;r;rpf;Frk;ge;jkhfNehapd; jd;ikgw;wpAk; kw;wtpguq;fSf;Fk; 
Muha;r;rpahsu; kUj;Jtu;: jp.Rthjpdp (gl;lNkw;g;gbg;ghsu;>Foe;ijkUj;Jtj; 
Jiw) mtu;fisve;jNeuj;jpYk; njhlu;Gnfhs;syhk;. ifg;Ngrpvz;:9087674097. 
NkYk; ,e;jMuha;r;rpf;Fjf;fmDkjpr; rhd;W (IEC) ngwg;gl;Ls;sJ. 
 ,e;j;wpYk; ghJfhg;ghd %ypifnghUl;fisf; 
nfhz;Ljahhpf;fg;gl;Ls;sJ. gf;ftpisTfisVw;gLj;jhJ. NkYk; 
czTKiwapy; kUj;Jtuhy; $wg;gLk; gj;jpak; fhf;FkhWmwpTWj;jgLfpwJ. 
      ,J rk;gjkhdjq;fsJmidj;Jtptuq;fSk; ufrpakhfitf;fg;gLk; 
vdcWjpmspf;fpNwd;. 
      ,jpy; gazg;gbKjypave;jcjtpj; njhifAk; toq;fg;glkhl;lhJ. 
,e;jMuha;r;rpapd; NghJclYf;FNtWghjpg;GVw;gLk; gl;rj;jpy; mwpQu; 
mz;zhkUj;Jtkidapy; jf;frpfpr;irmspf;fg;gLk;. 
 
 
அரசின��சித்��மதத்��க்�க 
அறிஞ��அண ண்��இ ி்த��மதத்�� �்ைச��ன- 10 6  
கரப்ண��்�ணதணயாக��க��ப ட்ப�க�்்ணபத�வ்்�்�ிண�றக� 
 
வ் ட்்�்ச��க�்்ணபத�்�: 
• ்ச�சகணாகறிக� 
• கீ�ர்�கக� 
• ி்க்்ண�ச�ை்ணமடக� (ஏலம, �ஞச�, சீரகம, ை்மஙகணதம, �ிய�, 
���, ை்இ்தம, �ண்) 
• ண�யகடபத்ணனாதஙக� 
• ்�் �கக� 
• ்ண்ண� 
வ் ட்்�் ட்��க�்்ணபத�் 
• கரப்ண�்ண�ஙகயணன்ர�, கம ,் ்சணயம, ்ண���கணா, ்ணகறகணா 
• �� ்�கக�, ணட��, கம்ண், ்கண�ி�கறி 
• கத்க�கணா 
• ்யா 
• ஊ�கணா்�கக� 
• அ ி்கஅய்வப் 
 
 
 
GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
CLINICAL STUDY ON “SAARANAI ENNAI” IN THE TREATMENT OF 
“BALA KARAPPAN’’ (ATOPIC DERMATITIS) IN CHILDREN 
 
FORM X - ADVERSE REACTION REPORTING FORM 
SERIAL NO  :                                                                                                           
OP/IP NO  : 
NAME  :                     
AGE   :                                                  
GENDER  : 
DATE OF TRIAL COMMENCEMENT: 
DATE OF OCCURRENCE OF THE ADVERSE REACTION:             
TIME   : 
DESCRIPTION OF ADVERSE REACTION: 
 
MANAGEMENT : 
 
 
Date:                                                                              
Station: 
 
Signature of the Guide                                                 Signature of the Investigator 
 
 
 
DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
DISSERTATION STUDY ON SAARANAI ENNAI IN 
BALA KARAPPAN (ATOPIC DERMATITIS) IN CHILDREN 
INVESTIGATOR- DR.T.SWATHINI 
ANNA HOSPITAL OPD-CHENNAI-106 
OPNO/DATE: 
Name  : 
Age/sex : 
Parent name : 
Address : 
 
Pnone no : 
COMPLAINTS AND DURATION: 
Erythema,itching,papules,oozing,scaling, 
Vesicles,pustules,oedema,ulcer/ 
Lichenification 
SITES   : 
STAGE  :   ACUTE /  SUBACUTE/ CHRONIC 
MODE OF ONSET :   ACUTE/   CHRONIC 
ECONOMIC STATE: POOR / MIDDLE / RICH 
DIET   : VEG/MIXED 
FAMILY HISTORY : 
PAST HISTORY : 
CONTACY ALLERGY/FOOD ALLRGY: 
ON EXAMINATION: 
PALLOR                       
HT                          
WT                        
 
 
CVS 
RS 
OTHERS 
ENVAGAI THERVU: 
Naa :      Malam  : 
Niram :   Moothiram : 
Mozhi :      Naadi  : 
Vizhi :      Sparisam : 
INVESTIGATION 
 BEFORE TREATMENT AFTER TREATMENT 
Tc 
Blood 
Dc 
Hb 
Esr 
Alb 
Urine 
Sug 
Dep 
Ova 
Motion 
Cyst 
 
others 
 
 
TREATMENT 
 
 
W
E
E
K
S/
D
A
TE
 
E
ry
th
em
a 
itc
hi
ng
 
V
es
ic
le
s, 
oo
zi
ng
 
Sc
al
in
g/
 
pu
st
ul
es
 
O
ed
em
a/
 
U
lc
er
 
lic
he
ni
fic
at
io
n 
I       
II       
III       
IV       
V       
VI       
VII       
 
RECURRENCE: 
RESULTS: 
 
 
EASI SCORE ASSESSMENT: 
EASI SCORE 0 day 7th 14th 21st 
     
 
ECZEMA AREA AND SEVERITY INDEX (EASI): 
  
R - Redness   T - Thickness     
S-Scratching                          L -Lichenification 
 
EASI=0.1(EH+TH+SH+LH)AH+0.2(EU+TU+SU+LU)AU+0.3(ET+TT+ST+LT)AT+0.4(EL+TL
+SL+LL)AL 
 
Redness/ Thickness/Scratching/Lichenification scoring:              AreaScoring: 
           
   
0 - Nil         0-Nil  
1- Mild    1-1-9% 
2- Moderate    2- 10-29% 
3-Severe    3-30-49%  
    4-50-69%  
    5-70-89%   
    6-90-100%  
                               EASI Calculation 
Patient name 
  
Date 
  
 
RATING SCORE 0=Nil 1=Mild 2=Moderate 3=Severe 
SEVERITY 
SCORE  
Body region and  Area score  
Head/Nec
k 
Uppe
r 
Limb
s 
Tru  
Lowe
r 
Limb
s 
Erythema     
     
 
 
Thicness 
 
  
      
Scratching 
 
  
      
Lichenification 
 
     
 Weighting factor                                                  
x 0.1 0.2 
0.
3 0.4 
Involvement Total                                                 
=     
Surface area  
    
  
Degree of involvement as  
% for each body region  
affected (score each  
region between 0 and 6) 
0 = None 
1 = 1-9% 
2 = 10-29% 
3 = 30-49% 
4 = 50-69% 
5 = 70-89% 
6 = 90-
100% 
Surface Area Total                                                  
=      
     
Involvement Total x Surface Area Total             
=     
TOTAL SCORE                                                 =  
 
Date:      
Station: 
 
Signature of the Guide                                               Signature of the Investigator                   
 
 
  
 
 
GOVT SIDDHA MEDICAL COLLEGE AND HOSPITAL CHENNAI 
Branch -IV KUZHANTHAI MARUTHUVAM 
PROFORMA OF CASE SHEET FOR BALA KARAPPAN 
OP. No :     Nationality   :  
Name   :     Religion   :  
Age   :     Date of Admission  :  
Sex   :     Date of Discharge  :  
Address :     Diagnosis   :  
Informant :     Medical Officer  :  
 
1. Complaints and duration  : 
2. History of present illness  : 
3. History of Past illness  : 
4. Antenatal history   : 
5. Birth history   : 
6. Neonatal history   : 
7. Developmental history  : 
8. Nutritional history   : 
9. Immunization history  : 
10. Family history   : 
11. Socio economic status  : 
 
General examination  
1. Appearance and posture : 
2. Nutritional status   : 
 
 
3. Anaemia   : 
4. Cyanosis   : 
5. Clubbing   : 
6. Jaundice   : 
7. Lymphadenopathy  : 
8. Abdominal distension : 
9. Pedal oedema  : 
Vital Signs  
1. Temperature  : 
2. Pulse rate   : 
3. Respiratory rate  : 
4. Heart rate   : 
5. Blood pressure  : 
Anthropometry  
a. Height   : 
b. Weight   : 
c .Chest circumference :  
SIDDHA ASPECTS  
Nilam 
1. Kurinji : 
2. Mullai : 
3. Marutham : 
4. Neithal : 
5. Paalai : 
 
 
Paruvakaalam 
1. Kaar : 
2. Koothir : 
3. Munpani : 
4. Pinpani : 
5. Elavenil : 
6. Muthuvenil : 
Poripulangal  
1. Mei   : 
2. Vai  : 
3. Kan  : 
4. Mooku : 
5. Sevi : 
Kanmenthiriyam 
1. Kai   : 
2. Kaal : 
3. Vaai : 
4. Eruvai : 
5. Karuvai : 
 
 
Uyirthathukkal 
Vadham 
1. Praanan : 
2. Abaanan : 
3. Viyaanan : 
4. Uthaanan : 
5. Samaanan : 
6. Naagan : 
7. Koorman : 
8. Kirukaran : 
9. Devathathan : 
10. Dhananjeyan : 
Pitham 
1. Analpitham : 
2. Ranjagam : 
3. Saadhagam : 
4. Praasagam : 
5. Aalosagam : 
Kabam 
1. Avalambagam : 
2. Kiletham  : 
3. Pothagam  : 
4. Tharpagam  : 
5. Santhigam  : 
 
 
Udalkattugal 
1. Saaram : 
2. Senneer : 
3. Oonn : 
4. Kozhuppu : 
5. Enbu : 
6. Moolai : 
7. Sukkilam / Suronitham:  
Envagaithervugal 
1. Naadi : 
2. Sparisam : 
3. Naa  : 
4. Niram : 
5. Mozhi : 
6. Vizhi : 
7. Malam  : 
8. Moothiram : 
MODERN ASPECTS  
1. Respiratory System  : 
2. Cardiovascular system  : 
3. Gastro intestinal system  : 
4. Central nervous system  : 
5. Excretory system   : 
 
 
Signs and Symptoms of BalaKarappan 
Itching : 
Papules : 
Erythema : 
Vesicles : 
Scaling : 
Oozing : 
Hyperpigmentation: 
Laboratory investigations  
Blood  
TC  : 
DC  : 
ESR   
1/2 hr: 
1 hr  : 
Hb%  : 
Urine  
Albumin : 
Sugar   : 
Deposits  : 
Investigation -Siddha aspect  
1. Neerkuri 
Niram  : 
Edai  : 
 
 
Manam : 
Nurai  :  
Enjal  : 
2. Neikuri 
3. Trial Drugs: 
Saaranaiennai(Internal& External) 
          6 to 12 yrs: 1-2 ml (int) and 30 ml (ext) 
 
3.Daily progress  
Date Symptoms  Medicine  
   
   
   
   
   
   
 
 
 
 
 
 
 
 
GOVT. SIDDHA MEDICAL COLLEGE AND HOSPITAL, 
POST GRADUATE DEPARTMENT. CHENNAI. 
Branch -IV KUZHANTHAI MARUTHUVAM 
ADMISSION - DISCHARGE CASE SHEET 
Name of the Medical Unit: 
IP. NO   : 
Bed no   : 
Ward    : 
Name    : 
Age    : 
Sex   : 
Permanent address : 
Temporary address : 
Informant   : 
S.No CLINICALFEATURES  (Signs and Symptoms) During Admission During Discharge 
1    
2    
3    
4    
5    
6    
7    
8    
9    
10    
 
 
Occupation  : 
Income  : 
Nationality  : 
Religion : 
Date of Admission: 
Date of discharge: 
Diagnosis  : 
Medicalofficer : 
 
